AGILENT TECHNOLOGIES, INC., 10-Q filed on 3/3/2026
Quarterly Report
v3.25.4
Document and Entity Information - shares
 3 Months Ended
Jan. 31, 2026
Feb. 25, 2026
Document and Entity Information [Abstract]    
Entity Registrant Name AGILENT TECHNOLOGIES, INC.  
Entity Central Index Key 0001090872  
Entity Incorporation, State or Country Code DE  
Document Type 10-Q  
Document Period End Date Jan. 31, 2026  
Document Fiscal Period Focus Q1  
Current Fiscal Year End Date --10-31  
Document Fiscal Year Focus 2026  
Entity Filer Category Large Accelerated Filer  
Entity File Number 001-15405  
Entity Tax Identification Number 77-0518772  
Entity Address, Address Line One 5301 Stevens Creek Blvd.,  
Entity Address, City or Town Santa Clara,  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 95051  
City Area Code (800)  
Local Phone Number 227-9770  
Document Quarterly Report true  
Document Transition Report false  
Title of 12(b) Security Common Stock, $0.01 par value  
Trading Symbol A  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Amendment Flag false  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   282,602,317
v3.25.4
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (Unaudited) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Net revenue:    
Net revenue $ 1,798 $ 1,681
Costs and expenses:    
Cost of revenue 852 782
Research and development 117 113
Selling, general and administrative 476 410
Total costs and expenses 1,445 1,305
Income from operations 353 376
Interest income 15 15
Interest expense (25) (28)
Other income (expense), net 21 4
Income before taxes 364 367
Provision for income taxes 59 49
Net income $ 305 $ 318
Net income per share    
Basic $ 1.08 $ 1.12
Diluted $ 1.07 $ 1.11
Weighted average shares used in computing net income per share:    
Basic 283 285
Diluted 284 287
Product    
Net revenue:    
Net revenue $ 1,273 $ 1,200
Costs and expenses:    
Cost of revenue 571 535
Services and Other    
Net revenue:    
Net revenue 525 481
Costs and expenses:    
Cost of revenue $ 281 $ 247
v3.25.4
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Net income $ 305 $ 318
Other comprehensive income (loss):    
Unrealized gain (loss) on derivative instruments, net of tax expense (benefit) of $(3) and $3 (7) 11
Amount reclassified into earnings related to derivative instruments, net of tax expense (benefit) of $1 and $(1) 1 (2)
Foreign currency translation, net of tax expense (benefit) of $0 and $0 51 (85)
Net defined benefit pension cost and post retirement plan costs:    
Change in actuarial net gain (loss), net of tax expense (benefit) of $0 and $0 (3) 0
Other comprehensive income (loss) 42 (76)
Total comprehensive income $ 347 $ 242
v3.25.4
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) (Parenthetical) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Other comprehensive income (loss), tax, parenthetical disclosures    
Unrealized gain (loss) on derivative instruments, tax expense (benefit) - TAX $ (3) $ 3
Amounts reclassified into earnings related to derivative instruments, tax expense (benefit) - TAX 1 (1)
Foreign currency translation, tax expense (benefit) - TAX 0 0
Net defined benefit pension cost and post retirement plan costs, tax    
Change in actuarial net gain (loss), tax expense (benefit) - TAX $ 0 $ 0
v3.25.4
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Millions
Jan. 31, 2026
Oct. 31, 2025
Current assets:    
Cash and cash equivalents $ 1,758 $ 1,789
Accounts receivable, net 1,521 1,487
Inventory 1,059 1,025
Other current assets 277 293
Total current assets 4,615 4,594
Property, plant and equipment, net 2,078 2,023
Goodwill 4,484 4,473
Other intangible assets, net 426 445
Long-term investments 135 133
Other assets 1,075 1,059
Total assets 12,813 12,727
Current liabilities:    
Accounts payable 602 570
Employee compensation and benefits 297 443
Deferred revenue 682 624
Short-term debt 304 304
Other accrued liabilities 349 406
Total current liabilities 2,234 2,347
Long-term debt 3,050 3,050
Retirement and post-retirement benefits 130 126
Other long-term liabilities 491 463
Total liabilities 5,905 5,986
Commitments and Contingencies (Note 12)
Stockholders' equity:    
Preferred stock; $0.01 par value; 125,000,000 shares authorized; none issued and outstanding at January 31, 2026 and October 31, 2025 0 0
Common stock; $0.01 par value; 2,000,000,000 shares authorized; 282,695,763 shares at January 31, 2026 and 283,054,377 shares at October 31, 2025, issued and outstanding 3 3
Additional paid-in-capital 5,605 5,575
Retained earnings 1,484 1,389
Accumulated other comprehensive loss (184) (226)
Total stockholder's equity 6,908 6,741
Total liabilities and stockholders' equity $ 12,813 $ 12,727
v3.25.4
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares
Jan. 31, 2026
Oct. 31, 2025
Stockholders' equity:    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 125,000,000 125,000,000
Preferred Stock, Shares Issued 0 0
Preferred stock, outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 2,000,000,000 2,000,000,000
Common Stock, Shares, Issued 282,695,763 283,054,377
Common Stock, Shares, Outstanding 282,695,763 283,054,377
v3.25.4
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Cash flows from operating activities    
Net income $ 305 $ 318
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 67 72
Share-based compensation 41 40
Deferred taxes expense (benefit) 25 (10)
Excess and obsolete inventory related charges 10 10
Net gain (loss) on equity securities 2 1
Other non-cash income (expense), net (2) 0
Changes in assets and liabilities:    
Accounts receivable,net (18) (30)
Inventory (39) (40)
Accounts payable 39 3
Employee compensation and benefits (151) (104)
Other assets and liabilities (11) 173
Net cash provided by operating activities 268 431
Cash flows from Investing activities:    
Payments to acquire property, plant and equipment (93) (97)
Payments in exchange for convertible note 0 (1)
Payments to acquire businesses and intangible assets, net of cash acquired 0 4
Net cash used in investing activities (93) (94)
Cash flows from financing activities:    
Proceeds from issuance of common stock under employee stock plans 31 30
Payment of taxes related to net share settlement of equity awards (27) (22)
Payments for repurchase of common stock (152) (90)
Payment of dividends (72) (71)
Proceeds from Issuance of Long-Term Debt 0 4
Repayments of Long-Term Debt (2) (1)
Net Proceeds from (Repayments of) Short-Term Debt 0 (30)
Net cash used in financing activities (222) (180)
Effect of Exchange Rate Movements 16 (19)
Net increase (decrease) in cash, cash equivalents and restricted cash (31) 138
Cash, cash equivalents and restricted cash at beginning of period 1,791 1,332
Cash, cash equivalents and restricted cash at end of period 1,760 1,470
Supplemental cash flow information:    
Income tax paid, net of refunds received 105 19
Interest payments, net of capitalized interest 1 3
Net change in property, plant and equipment included in Accounts Payable and Accrued Liabilities increase (decrease) $ (11) $ 8
v3.25.4
CONDENSED CONSOLIDATED STATEMENT OF EQUITY - USD ($)
shares in Thousands, $ in Millions
Total
Common Stock
Additional Paid-in Capital
Retained Earnings
Accumulated Other Comprehensive Loss
Total Stockholder's Equity
Beginning Balance (in Shares) at Oct. 31, 2024   285,193        
Beginning Balance at Oct. 31, 2024   $ 3 $ 5,450 $ 750 $ (305) $ 5,898
Components of comprehensive income, net of tax            
Net income $ 318     318   318
Other comprehensive income (loss) (76)       (76) (76)
Total comprehensive income, net of tax           242
Cash dividends declared       (71)   (71)
Share-based awards issued, net of tax (in shares)   689        
Share-based awards issued     8     8
Stock Repurchased and Retired During Period, Shares   (650)        
Stock Repurchased and Retired During Period, Value     (9) (81)   (90)
Share-based compensation     40     40
Ending Balance (in Shares) at Jan. 31, 2025   285,232        
Ending Balance at Jan. 31, 2025   $ 3 5,489 916 (381) 6,027
Beginning Balance (in Shares) at Oct. 31, 2025   283,054        
Beginning Balance at Oct. 31, 2025 6,741 $ 3 5,575 1,389 (226) 6,741
Components of comprehensive income, net of tax            
Net income 305     305   305
Other comprehensive income (loss) 42       42 42
Total comprehensive income, net of tax           347
Cash dividends declared       (72)   (72)
Share-based awards issued, net of tax (in shares)   692        
Share-based awards issued     4     4
Stock Repurchased and Retired During Period, Shares   (1,050)        
Stock Repurchased and Retired During Period, Value     (15) (138)   (153)
Share-based compensation     41     41
Ending Balance (in Shares) at Jan. 31, 2026   282,696        
Ending Balance at Jan. 31, 2026 $ 6,908 $ 3 $ 5,605 $ 1,484 $ (184) $ 6,908
v3.25.4
CONDENSED CONSOLIDATE STATEMENT OF EQUITY - (PARENTHETICAL) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Statement of Stockholders' Equity [Abstract]    
Dividends Declared per share $ 0.255 $ 0.248
Share-based Award, Tax $ 27 $ 22
v3.25.4
OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Notes)
 3 Months Ended
Jan. 31, 2026
Accounting Policies [Abstract]  
OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Overview. Agilent Technologies, Inc. ("we," "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.

Our fiscal year-end is October 31, and our fiscal quarters end on January 31, April 30 and July 31. Unless otherwise stated, these dates refer to our fiscal year and fiscal quarters.

Basis of Presentation. We have prepared the accompanying financial data for the three months ended January 31, 2026 and 2025 pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles ("GAAP") in the U.S. have been condensed or omitted pursuant to such rules and regulations. The October 31, 2025 condensed balance sheet data was derived from audited financial statements but does not include all the disclosures required in audited financial statements by U.S. GAAP. The accompanying financial data and information should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended October 31, 2025.

In the opinion of management, the accompanying condensed consolidated financial statements contain all normal and recurring adjustments necessary for a fair statement of our condensed consolidated balance sheets as of January 31, 2026 and October 31, 2025, condensed consolidated statement of comprehensive income for the three months ended January 31, 2026 and 2025, condensed consolidated statement of operations for the three months ended January 31, 2026 and 2025, condensed consolidated statement of cash flows for the three months ended January 31, 2026 and 2025 and condensed consolidated statement of equity for the three months ended January 31, 2026 and 2025.

Risks and Uncertainties. We are subject to risks common to companies in the analytical instrument industry, such as global economic and financial market conditions, fluctuations in foreign currency exchange rates and fluctuations in customer demand, among others.

While the tariff changes adversely impacted our costs of revenue during the three months ended January 31, 2026, we expect to fully offset the current impact during our fiscal year 2026. Although the tariff situation is still evolving, we expect to pursue mitigation strategies through supply chain optimization, targeted pricing actions, and other cost-efficiency initiatives to protect margins and sustain long-term growth. Additionally, recent judicial rulings in the U.S. on the legality of certain tariffs imposed and potential future U.S. governmental responses further increase the uncertainty as to the impact of tariffs on our future results of operations. We will continue to monitor these evolving trade dynamics closely, as they may influence future revenue and operational efficiency.

Use of Estimates. The preparation of condensed consolidated financial statements in accordance with GAAP in the U.S. requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, valuation of goodwill and purchased intangible assets, inventory valuation, retirement and post-retirement benefit plan assumptions and accounting for income taxes.
Restricted Cash and Restricted Cash Equivalents. Restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets follows:
 January 31,October 31,
 20262025
(in millions)
Cash and cash equivalents$1,758 $1,789 
Restricted cash included in other assets2 2 
Total cash, cash equivalents and restricted cash$1,760 $1,791 

Leases. As of January 31, 2026 and October 31, 2025, operating lease right-of-use assets where we are the lessee were $189 million and $183 million, respectively, and were included within other assets in the accompanying condensed consolidated balance sheets. The associated operating lease liabilities were $196 million and $189 million as of January 31, 2026 and October 31, 2025, respectively, and were included in other accrued liabilities and other long-term liabilities in the accompanying condensed consolidated balance sheets.

Variable Interest Entities. We make a determination upon entering into an arrangement whether an entity in which we have made an investment is considered a Variable Interest Entity ("VIE"). We evaluate our investments in privately held companies on an ongoing basis. We have determined that as of January 31, 2026 and October 31, 2025, there were no VIEs required to be consolidated in our consolidated financial statements because we do not have a controlling financial interest in any of the VIEs in which we have invested nor are we the primary beneficiary. We account for these investments under either the equity method or as equity investments without readily determinable fair value ("RDFV"), depending on the circumstances. We periodically reassess whether we are the primary beneficiary of a VIE. The reassessment process considers whether we have acquired the power to direct the most significant activities of the VIE through changes in governing documents or other circumstances. We also reconsider whether entities previously determined not to be VIEs have become VIEs and vice-versa, based on changes in facts and circumstances including changes in contractual arrangements and capital structure.

As of January 31, 2026 and October 31, 2025, the total carrying value of investments and loans in privately held companies considered as VIEs was $44 million. The maximum exposure is equal to the carrying value because we do not have future funding commitments. The investments are classified as long-term investments and the loans are classified within other current assets and other assets (depending upon tenure of loan) on the condensed consolidated balance sheets.

Fair Value of Financial Instruments. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of long-term equity investments which are readily determinable, and which are not accounted under the equity method are reported at fair value using quoted market prices for those securities when available with gains and losses included in net income. The fair value of long-term equity investments which are not readily determinable, and which are not accounted under the equity method are reported at cost with adjustments for observable changes in prices or impairments included in net income. As of January 31, 2026 and October 31, 2025, the fair value of the commercial paper approximates its carrying value. As of January 31, 2026, the fair value of our senior notes was $3,207 million with a carrying value of $3,332 million. This compares to the fair value of our senior notes of $3,191 million with a carrying value of $3,330 million as of October 31, 2025. The change in the fair value in the three months ended January 31, 2026 is primarily due to increased market interest rates. The fair value was calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs, for example, interest rate yield curves, foreign exchange rates, and forward and spot prices for currencies are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See Note 9, "Fair Value Measurements" for additional information on fair value of financial instruments.
v3.25.4
NEW ACCOUNTING PRONOUNCEMENTS (Notes)
 3 Months Ended
Jan. 31, 2026
Accounting Policies [Abstract]  
NEW ACCOUNTING PRONOUNCEMENTS NEW ACCOUNTING PRONOUNCEMENTS
There were no additions to the new accounting pronouncements not yet adopted as described in our Annual Report on Form 10-K for the fiscal year ended October 31, 2025.

Other amendments to GAAP in the U.S. that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our condensed consolidated financial statements upon adoption.
v3.25.4
REVENUE (Notes)
 3 Months Ended
Jan. 31, 2026
Revenue from Contract with Customer [Abstract]  
Revenue from Contract with Customer REVENUE
The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:
Three Months Ended January 31,
20262025
Life Sciences and Diagnostics MarketsAgilent CrossLabApplied MarketsTotalLife Sciences and Diagnostics MarketsAgilent CrossLabApplied MarketsTotal
(in millions)
Revenue by Region
Americas$307 $273 $98 $678 $312 $261 $96 $669 
Europe203 215 100 518 190 188 85 463 
Asia Pacific169 270 163 602 145 247 157 549 
Total$679 $758 $361 $1,798 $647 $696 $338 $1,681 
The following table presents the company’s total revenue disaggregated by end markets and by revenue type:
Three Months Ended
January 31,
20262025
(in millions)
Revenue by End Markets
Pharmaceutical and Biotechnology$640 $585 
Diagnostics and Clinical263 240 
Academia and Government130 137 
Chemicals and Advanced Materials422 379 
Food166 168 
Environmental and Forensics177 172 
Total$1,798 $1,681 
Revenue by Type
Instrumentation$658 $625 
Non-instrumentation and other1,140 1,056 
Total$1,798 $1,681 

Revenue by region is based on the ship to location of the customer. Revenue by end market is determined by the market indicator of the customer and by customer type. Instrumentation revenue includes sales from instruments, remarketed instruments and third-party products. Non-instrumentation revenue includes sales from contract and per incident services, companion diagnostics, contract development and manufacturing, spare parts, consumables, reagents, vacuum pumps, subscriptions, software licenses and associated services.
Contract Balances

Contract Assets

Contract assets (unbilled accounts receivable) primarily relate to the company's right to consideration for work completed but not billed at the reporting date. The unbilled receivables are reclassified to trade receivables when billed to customers. Contract assets are generally classified as current assets and are included in "Accounts receivable, net" in the condensed consolidated balance sheets. The balances of contract assets as of January 31, 2026 and October 31, 2025, were $286 million and $329 million, respectively.

Contract Liabilities

The following table provides information about contract liabilities (deferred revenue) and the changes in the balances during the three months ended January 31, 2026:
Contract
Liabilities
(in millions)
Ending balance as of October 31, 2025$803 
Net revenue deferred in the period301 
Revenue recognized that was included in the contract liability balance at the beginning of the period(250)
Change in deferrals from customer cash advances, net of revenue recognized10 
Currency translation and other adjustments13 
Ending balance as of January 31, 2026$877 

During the three months ended January 31, 2025 revenue recognized that was included in the contract liability balance at October 31, 2024 was $230 million.

Contract liabilities primarily relate to multiple element arrangements for which billing has occurred but transfer of control of all elements to the customer has either partially or not occurred at the balance sheet date. This includes cash received from customers for products and related installation and services in advance of the transfer of control. Contract liabilities are classified as either current in deferred revenue or long-term in other long-term liabilities in the condensed consolidated balance sheets based on the timing of when we expect to complete our performance obligation.

Contract Costs

Incremental costs of obtaining a contract with a customer are recognized as an asset if we expect the benefit of those costs to be longer than one year. We have determined that certain sales incentive programs meet the requirements to be capitalized. The change in total capitalized costs to obtain a contract was immaterial during the three months ended January 31, 2026, and was included in other current and long-term assets on the condensed consolidated balance sheet. We have applied the practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. These costs include the company's internal sales force compensation program, as we have determined that annual compensation is commensurate with annual sales activities.

Transaction Price Allocated to the Remaining Performance Obligations

We have applied the practical expedient in ASC 606-10-50-14 and have not disclosed information about transaction price allocated to remaining performance obligations that have original expected durations of one year or less.
The estimated revenue expected to be recognized for remaining performance obligations that have an original term of more than one year, as of January 31, 2026, was $459 million, the majority of which is expected to be recognized over the next 12 months. Remaining performance obligations primarily include extended warranty, customer manufacturing contracts, software maintenance contracts and revenue associated with lease arrangements.
v3.25.4
SHARE-BASED COMPENSATION (Notes)
 3 Months Ended
Jan. 31, 2026
Share-Based Payment Arrangement, Noncash Expense [Abstract]  
SHARE-BASED COMPENSATION SHARE-BASED COMPENSATION
 
We account for share-based awards in accordance with the provisions of the authoritative accounting guidance which requires the measurement and recognition of compensation expense for all share-based payment awards made to our employees and directors including employee stock options, restricted stock units, employee stock purchases made under our employee stock purchase plan ("ESPP") and performance share awards granted to selected members of our senior management under the long-term performance plan ("LTPP") based on estimated fair values.

Performance Stock Units. We have two LTPP performance stock award programs, which are administered under the 2018 Stock Plan, for our executive officers and other key employees. Participants in our LTPP Total Stockholders’ Return ("TSR") and LTPP Earnings Per Share ("EPS") programs are entitled to receive shares of the company's stock after the end of a three-year period, if specified performance targets for the programs are met. The LTPP-TSR awards are generally designed to meet the criteria of a performance award with the performance metrics and peer group comparison based on the TSR set at the beginning of the performance period. The LTPP-EPS awards are based on the company’s EPS performance over a three-year period. The performance targets for the LTPP-EPS for year 2 and year 3 of the performance period are set in the first quarter of year 2 and year 3, respectively. For LTPP awards granted in fiscal year 2025, final payout of fiscal year 2025 awards will be further adjusted on achievement of predefined operating margin targets for fiscal year 2027. All LTPP awards granted through fiscal year 2025 are subject to a one-year post-vest holding period. The final LTPP award may vary from 0 percent to 200 percent of the target award. We consider the dilutive impact of these programs in our diluted net income per share calculation only to the extent that the performance conditions are expected to be met. Effective in fiscal year 2026, we have discontinued granting LTPP-EPS awards. In addition, LTPP-TSR awards granted in fiscal year 2026 are no longer subject to a one-year post-vest holding period.

Restricted Stock Units. Restricted stock units generally vest, with some exceptions, at a rate of 25 percent per year over a period of four years from the date of grant. All restricted stock units granted to our executives through fiscal year 2025 are subject to a one-year post-vest holding period. Effective in fiscal year 2026, all restricted stock units granted to our executives are no longer subject to a one-year post-vest holding period.

Stock Options. Stock options granted under the 2018 Stock Plan may be either "incentive stock options", as defined in Section 422 of the Internal Revenue Code, or non-statutory. Options generally vest at a rate of 25 percent per year over a period of four years from the date of grant with a maximum contractual term of ten years. The exercise price for stock options is generally not less than 100 percent of the fair market value of our common stock on the date the stock award is granted. We issue new shares of common stock when previously granted employee stock options are exercised. Effective in fiscal year 2026, we have discontinued granting employee stock options.
The impact on our results for share-based compensation was as follows:
 
Three Months Ended
January 31,
 20262025
 (in millions)
Cost of products and services$12 $12 
Research and development5 5 
Selling, general and administrative24 24 
Total share-based compensation expense$41 $41 
 
At January 31, 2026 and October 31, 2025, no share-based compensation was capitalized within inventory.
The following assumptions were used to estimate the fair value of awards granted.
 
Three Months Ended
January 31,
 20262025
Stock Option Plans:  
Weighted average risk-free interest rate—4.1%
Dividend yield—0.7%
Weighted average volatility—29%
Expected life—5.5 years
LTPP:
Volatility of Agilent shares29%30%
Volatility of selected peer-company shares
17%-59%
16%-62%
Pair-wise correlation with selected peers24%29%
Post-vest holding restriction discount for all executive awards(1)
6.5%6.7%
 _________________________________________________________________________________
(1) For the three months ended January 31, 2026, post-vest holding restriction discount assumption relates to LTPP awards granted to our senior management employees before November 1, 2025.


The fair value of share-based awards for our employee stock option awards was estimated using the Black-Scholes option pricing model. Shares granted under the LTPP-TSR were valued using a Monte Carlo simulation model. The Monte Carlo simulation fair value model requires the use of highly subjective and complex assumptions, including the price volatility of the underlying stock.  For the volatility of our LTPP-TSR grants, we used our own historical stock price volatility.  

The ESPP allows eligible employees to purchase shares of our common stock at 85 percent of the price at purchase and uses the purchase date to establish the fair market value.

We use historical volatility to estimate the expected stock price volatility assumption for employee stock option awards. In reaching the conclusion, we have considered many factors including the extent to which our options are currently traded and our ability to find traded options in the current market with similar terms and prices to the options we are valuing. In estimating the expected life of our options granted, we considered the historical option exercise behavior of our executives, which we believe is representative of future behavior.

The estimated fair value of restricted stock units and LTPP-EPS awards is determined based on the market price of our common stock on the date of grant adjusted for expected dividend yield. The compensation cost for LTPP-EPS reflects the cost of awards that are probable to vest at the end of the performance period.

All LTPP awards granted to our senior management employees through fiscal year 2025 have a one-year post-vest holding restriction. The estimated discount associated with post-vest holding restrictions is calculated using the Finnerty model. The model calculates the potential lost value if the employees were able to sell the shares during the lack of marketability period instead of being required to hold the shares. The model used the same historical stock price volatility and dividend yield assumption used for the Monte Carlo simulation model and an expected dividend yield to compute the discount.
v3.25.4
INCOME TAXES (Notes)
 3 Months Ended
Jan. 31, 2026
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
For the three months ended January 31, 2026, our income tax expense was $59 million with an effective tax rate of 16.2 percent. For the three months ended January 31, 2026, there were no significant discrete items.

For the three months ended January 31, 2025, our income tax expense was $49 million with an effective tax rate of 13.4 percent. For the three months ended January 31, 2025, there were no significant discrete items.

In the U.S., tax years remain open back to the year 2022 for federal income tax purposes and 2021 for significant states. In other major jurisdictions where we conduct business, the tax years generally remain open back to the year 2014.
With these jurisdictions and the U.S., it is reasonably possible that some tax audits may be completed over the next twelve months. However, management is not able to provide a reasonably reliable estimate of the timing of any other future tax payments or change in unrecognized tax benefits, if any.

The Organization for Economic Co-operation and Development. ("OECD") has introduced rules to establish a global minimum tax rate of 15 percent, commonly referred to as the Pillar Two rules. We have considered the impact of currently enacted Pillar Two rules, and our income taxes have increased due to top-up taxes. Additionally, the United States enacted the One Big Beautiful Bill Act ("OBBBA") on July 4, 2025, including adjustments to effective tax rates on certain types of income and an elective deduction for domestic Research and Development (R&D), which are applicable to Agilent in fiscal years 2026 and 2027. The OBBBA did not have a material impact on our effective tax rate or cash flow in the current quarter.
v3.25.4
NET INCOME PER SHARE (Notes)
 3 Months Ended
Jan. 31, 2026
Earnings Per Share [Abstract]  
NET INCOME PER SHARE NET INCOME PER SHARE
 
The following is a reconciliation of the numerator and denominator of the basic and diluted net income per share computations for the periods presented below:
 
Three Months Ended
January 31,
 20262025
 (in millions)
Numerator:  
Net income$305 $318 
Denominator:
Basic weighted-average shares283 285 
Potential common shares— stock options and other employee stock plans1 2 
Diluted weighted-average shares284 287 
 
The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense and the dilutive effect of in-the-money options and non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options and unamortized share-based compensation expense collectively are assumed proceeds to be used to repurchase hypothetical shares. An increase in the fair market value of the company's common stock can result in a greater dilutive effect from potentially dilutive awards.

We exclude stock options with exercise prices greater than the average market price of our common stock from the calculation of diluted earnings per share because their effect would be anti-dilutive. In addition, we exclude from the calculation of diluted earnings per share stock options, ESPP, LTPP and restricted stock awards whose combined exercise price and unamortized fair value were greater than the average market price of our common stock because their effect would also be anti-dilutive.  
For the three months ended January 31, 2026 and 2025, potential common shares excluded from the calculation of diluted earnings per share were not material.
v3.25.4
INVENTORY (Notes)
 3 Months Ended
Jan. 31, 2026
Inventory, Net [Abstract]  
INVENTORY INVENTORY
 
Inventory as of January 31, 2026 and October 31, 2025 consisted of the following:

 January 31,
2026		October 31,
2025
 (in millions)
Finished goods$546 $547 
Purchased parts and fabricated assemblies513 478 
Inventory$1,059 $1,025 
v3.25.4
GOODWILL AND OTHER INTANGIBLE ASSETS (Notes)
 3 Months Ended
Jan. 31, 2026
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS
 
The following table presents goodwill balances and the movements for each of our reportable segments during the three months ended January 31, 2026:
 
 Life Sciences and
Diagnostics Markets		Agilent CrossLabApplied MarketsTotal
 (in millions)
Goodwill as of October 31, 2025$2,996 $1,168 $309 $4,473 
Foreign currency translation impact1 3 7 11 
Goodwill as of January 31, 2026$2,997 $1,171 $316 $4,484 

The component parts of other intangible assets as of October 31, 2025 and January 31, 2026 are shown in the table below:
 
 Other Intangible Assets
 Gross
Carrying
Amount		Accumulated
Amortization		Net Book
Value
 (in millions)
As of October 31, 2025   
Purchased technology$1,484 $1,235 $249 
Trademark/Trade name199 181 18 
Customer relationships289 129 160 
Backlog9 2 7 
Third-party technology and licenses34 23 11 
Total amortizable intangible assets$2,015 $1,570 $445 
As of January 31, 2026   
Purchased technology$1,488 $1,249 $239 
Trademark/Trade name198 182 16 
Customer relationships289 135 154 
Backlog9 2 7 
Third-party technology and licenses34 24 10 
Total amortizable intangible assets$2,018 $1,592 $426 

During the three months ended January 31, 2026, there were no additions to goodwill or other intangible assets. During the three months ended January 31, 2026, there was no change in net book value of other intangible assets due to the impact of foreign currency.

In general, for U.S. federal tax purposes, goodwill from asset purchases is amortizable; however, any goodwill created as part of a stock acquisition is not deductible. 
Each quarter we review the events and circumstances to determine if impairment of indefinite-lived intangible assets and goodwill is indicated. During the three months ended January 31, 2026 and 2025, we did not identify any triggering events or circumstances which would indicate an impairment of goodwill or indefinite-lived intangible assets.

For the three months ended January 31, 2026 and 2025, amortization expense of intangible assets was $19 million and $28 million, respectively.

Future amortization expense related to existing finite-lived purchased intangible assets for the remainder of fiscal year 2026 and for each of the next five fiscal years and thereafter is estimated below:
Estimated future amortization expense:
(in millions)
Remainder of 2026$56 
2027$72 
2028$65 
2029$61 
2030$52 
2031$47 
Thereafter$73 
v3.25.4
FAIR VALUE MEASUREMENTS (Notes)
 3 Months Ended
Jan. 31, 2026
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
 
The authoritative guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, we consider the principal or most advantageous market and assumptions that market participants would use when pricing the asset or liability.

Fair Value Hierarchy

The guidance establishes a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into three levels. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. There are three levels of inputs that may be used to measure fair value:

Level 1- applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2- applies to assets or liabilities for which there are inputs other than quoted prices included within level 1 that are observable, either directly or indirectly, for the asset or liability such as: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in less active markets; or other inputs that can be derived principally from, or corroborated by, observable market data.

Level 3- applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
 
Financial assets and liabilities measured at fair value on a recurring basis as of January 31, 2026 were as follows:
 
  Fair Value Measurement at January 31, 2026 Using
 January 31,
2026
Quoted Prices
 in Active
 Markets for
 Identical Assets
 (Level 1)
Significant
 Other
 Observable
 Inputs
 (Level 2)
Significant
 Unobservable
 Inputs
 (Level 3)
 (in millions)
Assets:    
Short-term    
Cash equivalents (money market funds)$1,093 $1,093 $— $— 
Derivative instruments (foreign exchange contracts)11 — 11 — 
Long-term
Trading securities42 42 — — 
Other investments39 — 39 — 
Total assets measured at fair value$1,185 $1,135 $50 $— 
Liabilities:    
Short-term
Derivative instruments (foreign exchange contracts) $14 $— $14 $— 
Long-term
Deferred compensation liability42 — 42 — 
Total liabilities measured at fair value$56 $— $56 $— 

Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2025 were as follows:
 
  Fair Value Measurement at October 31, 2025 Using
 October 31,
2025
Quoted Prices
 in Active
 Markets for
 Identical Assets
 (Level 1)
Significant
 Other
 Observable
 Inputs
 (Level 2)
Significant
 Unobservable
 Inputs
 (Level 3)
 (in millions)
Assets:    
Short-term    
Cash equivalents (money market funds)$1,614 $1,614 $— $— 
Derivative instruments (foreign exchange contracts)14 — 14 — 
Long-term
Trading securities41 41 — — 
Other investments37 — 37 — 
Total assets measured at fair value$1,706 $1,655 $51 $— 
Liabilities:    
Short-term
Derivative instruments (foreign exchange contracts)$10 $— $10 $— 
Long-term
Deferred compensation liability41 — 41 — 
Total liabilities measured at fair value$51 $— $51 $— 
 
Our money market funds and trading securities are generally valued using quoted market prices and therefore are classified within level 1 of the fair value hierarchy. Our derivative financial instruments are classified within level 2, as there is not an active market for each hedge contract, but the inputs used to calculate the value of the instruments are tied to active markets. Our deferred compensation liability is classified as level 2 because, although the values are not directly based on quoted market prices, the inputs used in the calculations are observable.

Other investments represent shares we own in a special fund that targets underlying investments of approximately 40 percent in debt securities and 60 percent in equity securities. These shares have been classified as level 2 because, although the shares of the fund are not traded on any active stock exchange, each of the individual underlying securities are or can be derived
from similar securities traded on an active market and hence we have a readily determinable value for the underlying securities, from which we are able to determine the fair market value for the special fund itself.

Trading securities, which are comprised of mutual funds, bonds and other similar instruments, other investments and deferred compensation liability are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in net income. Certain derivative instruments are reported at fair value, with unrealized gains and losses, net of tax, included in accumulated other comprehensive income (loss) within stockholders' equity. Realized gains and losses from the sale of these instruments are recorded in net income.

Gains and losses reflected in other income (expense), net for our equity investments with readily determinable fair value ("RDFV") and equity investments without RDFV are summarized below:
Three Months Ended
January 31,
20262025
(in millions)
Net gain (loss) recognized during the period on equity securities$2 $1 
Less: Net gain (loss) on equity securities sold during the period$— $— 
Unrealized gain (loss) on equity securities $2 $1 

Impairment of Investments. There were no impairments of investments for the three months ended January 31, 2026 and 2025.
 
Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

For the three months ended January 31, 2026 and 2025, there were no impairments of long-lived assets held and used. For the three months ended January 31, 2026 and 2025, there were no impairments of long-lived assets held for sale.

Non-Marketable Equity Securities

For the three months ended January 31, 2026, the unrealized gain (loss) on our non-marketable equity securities without readily determinable fair values had no upward or downward adjustments and no impairments which were included in net income as adjustments to the carrying value.

As of January 31, 2026, the cumulative net gain (loss) on our non-marketable equity securities without readily determinable fair values was comprised of $42 million upward adjustments, $71 million downward adjustments and $26 million of impairments. As of January 31, 2026, the carrying amount of our non-marketable equity securities without readily determinable fair value was $55 million.

For the three months ended January 31, 2025, the unrealized gain (loss) on our non-marketable equity securities without readily determinable fair values was comprised of no upward adjustments, $1 million of downward adjustments and no impairments which were included in net income as adjustments to the carrying value.

As of January 31, 2025, the cumulative net gain (loss) on our non-marketable equity securities without readily determinable fair values was comprised of $40 million upward adjustments, $31 million downward adjustments and no impairments. As of January 31, 2025, the carrying amount of our non-marketable equity securities without readily determinable fair value was $100 million.
v3.25.4
DERIVATIVES (Notes)
 3 Months Ended
Jan. 31, 2026
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
DERIVATIVES DERIVATIVES
 
We are exposed to foreign currency exchange rate fluctuations and interest rate changes in the normal course of our business. As part of our risk management strategy, we use derivative instruments, primarily forward contracts to hedge economic and/or accounting exposures resulting from changes in foreign currency exchange rates.
 
Cash Flow Hedges
 
We enter into foreign exchange contracts to hedge our forecasted operational cash flow exposures resulting from changes in foreign currency exchange rates. These foreign exchange contracts, carried at fair value, have maturities between one and twelve months. These derivative instruments are designated and qualify as cash flow hedges under the criteria prescribed in the authoritative guidance and are assessed for effectiveness against the underlying exposure every reporting period. For open contracts as of January 31, 2026, changes in the time value of the foreign exchange contract are excluded from the assessment of hedge effectiveness and are recognized in cost of sales over the life of the foreign exchange contract. The changes in fair value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss). Amounts associated with cash flow hedges are reclassified to cost of sales in the condensed consolidated statement of operations when the forecasted transaction occurs. If it becomes probable that the forecasted transaction will not occur, the hedge relationship will be de-designated and amounts accumulated in other comprehensive income (loss) will be reclassified to other income (expense), net in the current period. Changes in the fair value of the ineffective portion of derivative instruments are recognized in other income (expense), net in the condensed consolidated statement of operations in the current period. We record the premium paid (time value) of an option on the date of purchase as an asset. For options designated as cash flow hedges, changes in the time value are excluded from the assessment of hedge effectiveness and are recognized in cost of sales over the life of the option contract. For the three months ended January 31, 2026 and 2025, ineffectiveness and gains and losses recognized in other income (expense), net due to de-designation of cash flow hedge contracts were not significant.

In February 2016, Agilent executed three forward-starting pay fixed/receive variable interest rate swaps for the notional amount of $300 million in connection with future interest payments to be made on our 2026 senior notes issued on September 15, 2016. These derivative instruments were designated and qualified as cash flow hedges under the criteria prescribed in the authoritative guidance. The swap arrangements were terminated on September 15, 2016 with a payment of $10 million, and we recognized this as a deferred loss in accumulated other comprehensive income (loss) which is being amortized to interest expense over the life of the 2026 senior notes. The remaining loss to be amortized related to the interest rate swap agreements at January 31, 2026 was $1 million.

In August 2019, Agilent executed treasury lock agreements for $250 million in connection with future interest payments to be made on our 2029 senior notes issued on September 16, 2019. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 6, 2019, and we recognized a deferred loss of $6 million in accumulated other comprehensive income (loss) which is being amortized to interest expense over the life of the 2029 senior notes. The remaining loss to be amortized related to the treasury lock agreements at January 31, 2026 was $2 million.

Net Investment Hedges

We enter into foreign exchange contracts to hedge net investments in foreign operations to mitigate the risk of adverse movements in exchange rates. These foreign exchange contracts are carried at fair value and are designated and qualify as net investment hedges under the criteria prescribed in the authoritative guidance. Changes in fair value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss) - translation adjustment and are assessed for effectiveness against the underlying exposure every reporting period. If our net investment changes during the year, the hedge relationship will be assessed and de-designated if the hedge notional amount is outside of prescribed tolerance with a gain/loss reclassified from other comprehensive income (loss) to other income (expense) in the current period. For the three months ended January 31, 2026, ineffectiveness and the resultant effect of any gains or losses recognized in other income (expense) due to de-designation of the hedge contracts were not significant.

Other Hedges
 
Additionally, we enter into foreign exchange contracts to hedge monetary assets and liabilities that are denominated in currencies other than the functional currency of our subsidiaries. These foreign exchange contracts are carried at fair value and do not qualify for hedge accounting treatment and are not designated as hedging instruments. Changes in value of the derivative instruments are recognized in other income (expense), net in the condensed consolidated statement of operations, in the current period, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities.
 
Our use of derivative instruments exposes us to credit risk to the extent that the counterparties may be unable to meet the terms of the agreement. We do, however, seek to mitigate such risks by limiting our counterparties to major financial institutions which are selected based on their credit ratings and other factors. We have established policies and procedures for mitigating credit risk that include establishing counterparty credit limits, monitoring credit exposures, and continually assessing the creditworthiness of counterparties.
A number of our derivative agreements contain threshold limits to the net liability position with counterparties and are dependent on our corporate credit rating determined by the major credit rating agencies. The counterparties to the derivative instruments may request collateralization, in accordance with derivative agreements, on derivative instruments in net liability positions.

The aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position as of January 31, 2026, was approximately $9 million. The credit-risk-related contingent features underlying these agreements had not been triggered as of January 31, 2026.

The number of open foreign exchange forward contracts and aggregated notional amounts by designation as of January 31, 2026 were as follows:

 Number of Open Forward
Contracts 		Aggregate Notional Amount
USD
Buy/(Sell)
 ($ in millions)
Derivatives designated as hedging instruments:
Cash Flow Hedges
Foreign exchange forward contracts384$(503)
Net Investment Hedges
Foreign exchange forward contracts3$(35)
Derivatives not designated as hedging instruments:
Foreign exchange forward contracts181$(135)

Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheets in accordance with the authoritative guidance.
The gross fair values and balance sheet location of derivative instruments held in the condensed consolidated balance sheets as of January 31, 2026, and October 31, 2025, were as follows:

Fair Values of Derivative Instruments
Asset DerivativesLiability Derivatives
 Fair Value Fair Value
Balance Sheet LocationJanuary 31,
2026		October 31, 2025Balance Sheet LocationJanuary 31,
2026		October 31,
2025
(in millions)
Derivatives designated as hedging instruments:     
Cash flow hedges 
Foreign exchange contracts
Other current assets$5 $9 Other accrued liabilities$8 $3 
Net investment hedges
Foreign exchange contracts
Other current assets$— $— Other accrued liabilities$1 $— 
Derivatives not designated as hedging instruments:     
Foreign exchange contracts     
Other current assets$6 $5 Other accrued liabilities$5 $7 
Total derivatives$11 $14  $14 $10 
The effects of derivative instruments for foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our condensed consolidated statement of operations were as follows:

Three Months Ended
January 31,
20262025
 (in millions)
Derivatives designated as hedging instruments:  
Cash Flow Hedges
Foreign exchange contracts:
Gain (loss) recognized in accumulated other comprehensive income (loss)$(10)$14 
Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales$(1)$3 
Gain (loss) reclassified from accumulated other comprehensive income (loss) into interest expense$(1)$— 
Gain on time value of forward contracts recorded in cost of sales$2 $1 
Net Investment Hedges
Foreign exchange contracts:
Gain (loss) recognized in accumulated other comprehensive income (loss) - translation adjustment$(1)$2 
Derivatives not designated as hedging instruments:
Gain (loss) recognized in other income (expense), net$1 $(2)
At January 31, 2026, the amount of existing net gain that is expected to be reclassified from accumulated other comprehensive income (loss) is $8 million. Within the next twelve months it is estimated that $6 million of loss included within the net amount of accumulated other comprehensive income (loss) will be reclassified to cost of sales in respect of cash flow hedges.
v3.25.4
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Notes)
 3 Months Ended
Jan. 31, 2026
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]  
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS
Components of net periodic benefit cost (income). For the three months ended January 31, 2026 and 2025, our net pension and post retirement benefit cost (income) were comprised of the following:
 
Three Months Ended January 31,
 U.S.
Defined Benefit Plans		Non-U.S.
Defined Benefit Plans		U.S. Post Retirement
Benefit Plans
 202620252026202520262025
 (in millions)
Service cost - benefits earned during the period$— $— $6 $5 $— $— 
Interest cost on benefit obligation5 5 5 6 1 — 
Expected return on plan assets(6)(6)(12)(11)(2)(1)
Amortization of net actuarial (gain) loss— — (7)(6)— — 
Total net periodic benefit cost (income)$(1)$(1)$(8)$(6)$(1)$(1)
Settlements (gain) loss$— $— $— $14 $— $— 
The service cost component is recorded in cost of sales and operating expenses in the condensed consolidated statement of operations. All other cost components are recorded in other income (expense), net in the condensed consolidated statement of operations.

During the three months ended January 31, 2025, we transferred all the assets and obligations of our Netherlands defined benefit plan to an unaffiliated insurance company under a buy-out contract. The settlement resulted in a net loss of $14 million, which is included in other income (expense), net in the condensed consolidated statement of operations. The settlement loss includes the recognition of previously unrecognized actuarial losses that were included in accumulated other comprehensive income.
Employer contributions and expected future employer contributions for the remainder of the year were as follows:
Three Months Ended Employer Contributions
January 31,For Remainder of Year
202620252026
(in millions)
U.S. defined benefit plans$— $— $— 
Non-U.S. defined benefit plans$6 $6 $15 
v3.25.4
WARRANTIES AND CONTINGENCIES (Notes)
 3 Months Ended
Jan. 31, 2026
Commitments and Contingencies Disclosure [Abstract]  
WARRANTIES AND CONTINGENCIES WARRANTIES AND CONTINGENCIES
 
Warranties
 
We accrue for standard warranty costs based on historical trends in actual warranty charges over the past 12 months. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost over the period. The standard warranty accrual balances are held in other accrued and other long-term liabilities on our condensed consolidated balance sheets. Our standard warranty terms typically extend to one year from the date of delivery, depending on the product.
 
A summary of the standard warranty accrual activity is shown in the table below:
 
 Three Months Ended
January 31,
 20262025
 (in millions)
Standard warranty accrual, beginning balance$28 $30 
Accruals for warranties including change in estimates14 12 
Settlements made during the period(14)(13)
Standard warranty accrual, ending balance$28 $29 
Accruals for warranties due within one year$28 $29 
 
Bank Guarantees

Guarantees consist primarily of outstanding standby letters of credit and bank guarantees and were approximately $39 million as of January 31, 2026 and October 31, 2025. A standby letter of credit is a guarantee of payment issued by a bank on behalf of us that is used as payment of last resort should we fail to fulfill a contractual commitment with a third party. A bank guarantee is a promise from a bank or other lending institution that if we default on a loan, the bank will cover the loss.

Contingencies
 
We are involved in lawsuits, claims, investigations and proceedings, including, but not limited to, intellectual property, commercial, real estate, environmental and employment matters, which arise in the ordinary course of business. There are no matters pending that we currently believe are reasonably possible of having a material impact to our business, condensed consolidated financial condition, results of operations or cash flows.
v3.25.4
RESTRUCTURING AND OTHER RELATED COSTS (Notes)
 3 Months Ended
Jan. 31, 2026
Restructuring and Related Activities [Abstract]  
Restructuring and Related Activities Disclosure RESTRUCTURING AND OTHER RELATED COSTS
Fiscal Year 2025 Plan ("FY25 Plan")

In the second quarter of fiscal year 2025, we announced a restructuring plan designed to optimize our management structure to better serve our customers. The expense associated with this workforce reduction includes severance and other personnel-related costs. These actions impact all three of our business segments. The costs associated with this restructuring plan were not allocated to our business segments' results; however, each business segment will benefit from the future cost savings from these actions. When completed, the restructuring programs are expected to result in the reduction in annual cost of
sales and operating expenses over the three business segments.

A summary of our aggregate liability relating to the fiscal year 2025 restructuring plan and the total restructuring expense since inception of the plan are shown in the table below:

Workforce Reduction
Total
(in millions)
Balance at October 31, 2025$18 
Income statement expense20 
Non-cash settlement (accelerated share-based compensation expense)(3)
Cash payments(19)
Balance at January 31, 2026$16 
Total restructuring expense since inception of FY25 Plan$101 

In connection with the FY25 Plan, we have recorded approximately $20 million in restructuring and other related costs in the three months ended January 31, 2026. The restructuring liability of $16 million at January 31, 2026, is recorded in other accrued liabilities on the condensed consolidated balance sheet and reflects estimated future cash outlays. We expect to substantially complete these restructuring activities by the end of fiscal year 2026.

A summary of the charges in the condensed consolidated statement of operations resulting from restructuring activity is shown below:


Three Months Ended
January 31,
20262025
(in millions)
Cost of products and services$5 $— 
Research and development— — 
Selling, general and administrative(1)
15 1 
Total restructuring expense$20 $1 
___________________________________________________________________________________________________
(1) For the three months ended January 31, 2025, selling, general and administrative expense includes restructuring expense of $1 million related to the fiscal year 2024 restructuring plan that was completed in fiscal year 2025.
v3.25.4
SHORT-TERM DEBT (Notes)
 3 Months Ended
Jan. 31, 2026
Short-Term Debt [Abstract]  
SHORT-TERM DEBT SHORT-TERM DEBT
 
Credit Facilities
 
On June 7, 2023, we entered into a credit agreement with a group of financial institutions which provides for a $1.5 billion five-year unsecured credit facility that will expire on June 7, 2028 and an incremental revolving credit facility in an aggregate amount of up to $750 million. During the three months ended January 31, 2026, we made no borrowings or repayments under these credit facilities. As of both January 31, 2026 and October 31, 2025, we had no borrowings outstanding under either the credit facility or the incremental revolving credit facility.

On June 2, 2023, we entered into an Uncommitted Money Market Line Credit agreement with Societe Generale which provides for an aggregate borrowing capacity of $300 million. The credit facility is an uncommitted short-term cash advance facility where each request must be at least $1 million. The interest rate is set by the lender at the time of the borrowing and is fixed for the duration of the advance. During the three months ended January 31, 2026, we made no borrowings or repayments under this credit facility. As of both January 31, 2026 and October 31, 2025, we had no borrowings outstanding under the credit facility.

We were in compliance with the covenants for the credit facilities during the three months ended January 31, 2026.
Commercial Paper

Under our U.S. commercial paper program, the company may issue and sell unsecured, short-term promissory notes in the aggregate principal amount not to exceed $1.5 billion with up to 397-day maturities. At any point in time, the company intends to maintain available commitments under its revolving credit facility in an amount at least equal to the amount of the commercial paper notes outstanding. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The proceeds from issuances under the program may be used for general corporate purposes. During the three months ended January 31, 2026, we borrowed and repaid $225 million under our commercial paper program. As of both January 31, 2026 and October 31, 2025, we had no borrowings outstanding under our U.S. commercial paper program.

2026 Senior Notes

In 2025, we reclassified to short-term debt the aggregate principal amount of $300 million related to our 2026 senior notes with a maturity date of September 22, 2026. The notes bear interest at a fixed rate of 3.05% per annum.

Other Loans
We have two interest-free loans from the Strategic Innovation Fund ("SIF"). The loans are repayable in quarterly and yearly installments through 2040 at a weighted average imputed interest rate of 4.7 percent. In addition, we have two interest-free loans with the Atlantic Canada Opportunities Agency ("ACOA"). The loans are repayable in monthly installments through 2029 at a weighted average imputed interest rate of 4.5 percent. As of both January 31, 2026 and October 31, 2025, the current portion of these loans of $4 million was recorded in short-term debt.
v3.25.4
LONG-TERM DEBT (Notes)
 3 Months Ended
Jan. 31, 2026
Debt Disclosure [Abstract]  
LONG-TERM DEBT LONG-TERM DEBT
Senior Notes
 
The following table summarizes the company’s long-term senior notes:
 
 January 31, 2026October 31, 2025
 Amortized
Principal		Amortized
Principal
(in millions)
2027 Senior Notes597 597 
2029 Senior Notes497 497 
2030 Senior Notes498 498 
2031 Senior Notes846 845 
2034 Senior Notes594 593 
Total Senior Notes$3,032 $3,030 

All outstanding notes listed above are unsecured and rank equally in right of payment with all of Agilent’s other senior unsecured indebtedness. There have been no other changes to the principal, maturity, interest rates and interest payment terms of the Agilent senior notes, detailed in the table above, in the three months ended January 31, 2026, as compared to the senior notes described in our Annual Report on Form 10-K for the fiscal year ended October 31, 2025.

Other Loans
We have two interest-free loans from the Strategic Innovation Fund ("SIF"). The loans are repayable in quarterly and yearly installments through 2040 at a weighted average imputed interest rate of 4.7 percent. In addition, we have two interest-free loans with the Atlantic Canada Opportunities Agency ("ACOA"). The loans are repayable in monthly installments through 2029 at a weighted average imputed interest rate of 4.5 percent. During the three months ended January 31, 2026 we repaid $2 million of these loans. As of January 31, 2026 and October 31, 2025, the non-current portion of these loans of $18 million and $20 million, respectively, was recorded in long-term debt.
v3.25.4
STOCKHOLDERS' EQUITY (Notes)
 3 Months Ended
Jan. 31, 2026
Stockholders' Equity Note [Abstract]  
STOCKHOLDERS EQUITY STOCKHOLDERS' EQUITY
 
Stock Repurchase Programs
 
On January 9, 2023, we announced that our board of directors had approved a share repurchase program (the "2023 repurchase program") designed, among other things, to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs. The 2023 repurchase program authorizes the purchase of up to $2.0 billion, excluding excise taxes, of our common stock at the company's discretion and has no fixed termination date. The 2023 repurchase program does not require the company to acquire a specific number of shares and may be suspended, amended or discontinued at any time. The 2023 repurchase program commenced on March 1, 2023. During the three months ended January 31, 2025, we repurchased and retired 649,857 shares for $90 million under this authorization. As of September 2025, the 2023 repurchase program was completed.

On May 29, 2024, we announced that our board of directors had approved a new share repurchase program (the "2024 repurchase program") designed, among other things, to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs. The 2024 repurchase program authorizes the purchase of up to $2.0 billion, excluding excise taxes, of our common stock at the company's discretion and has no fixed termination date. The 2024 repurchase program does not require the company to acquire a specific number of shares and may be suspended, amended or discontinued at any time. The 2024 repurchase program became effective on August 1, 2024 and commenced in September 2025 upon the completion of our 2023 repurchase program. During the three months ended January 31, 2026 we repurchased and retired 1.050 million shares for $152 million, excluding excise taxes of $0.5 million under this authorization. As of January 31, 2026, we had remaining authorization to repurchase up to approximately $1,797 million of our common stock under the 2024 repurchase program.
 
Cash Dividends on Shares of Common Stock
 
During the three months ended January 31, 2026, we paid cash dividends of $0.255 per common share or $72 million on the company's common stock. During the three months ended January 31, 2025, we paid cash dividends of $0.248 per common share or $71 million on the company's common stock.

On February 11, 2026, our board of directors declared a quarterly dividend of $0.255 per share of common stock or approximately $72 million which will be paid on April 22, 2026, to shareholders of record as of the close of business on March 31, 2026. The timing and amounts of any future dividends are subject to determination and approval by our board of directors.

Accumulated Other Comprehensive Income (Loss)

Changes in accumulated other comprehensive income (loss) by component and related tax effects were as follows:
Net defined benefit pension cost and post retirement plan costs
Three Months Ended January 31, 2026Foreign currency translationPrior service creditsActuarial LossesUnrealized gains (losses) on derivativesTotal
(in millions)
As of October 31, 2025$(297)$120 $(64)$15 $(226)
Other comprehensive income (loss) before reclassifications51 — 4 (10)45 
Amounts reclassified out of accumulated other comprehensive income (loss)— — (7)2 (5)
Tax (expense) benefit— — — 2 2 
Other comprehensive income (loss)51 — (3)(6)42 
As of January 31, 2026$(246)$120 $(67)$9 $(184)
Reclassifications out of accumulated other comprehensive income (loss) for the three months ended January 31, 2026 and 2025 were as follows (in millions):
Details about accumulated other
comprehensive income (loss) components		Amounts Reclassified from
other comprehensive income (loss)		Affected line item in
statement of operations
Three Months Ended
January 31,
20262025
Unrealized gain (loss) on derivatives(1)3 Cost of products
Unrealized gain (loss) on derivatives(1)— Interest expense
(2)3 Total before income tax
1 (1)(Provision) benefit for income tax
(1)2 Total net of income tax
Net defined benefit pension cost and post retirement plan costs:
Actuarial net gain (loss)7 — Other income (expense), net
7 — Total before income tax
(1)— (Provision) benefit for income tax
6 — Total net of income tax
Total reclassifications for the period$5 $2 

Amounts in parentheses indicate reductions to income and increases to other comprehensive income (loss).

Reclassifications out of accumulated other comprehensive income (loss) of actuarial net gain (loss) in respect of retirement plans and post retirement pension plans are included in the computation of net periodic benefit cost (income) (see Note 11, "Retirement Plans and Post Retirement Pension Plans" for additional information).
v3.25.4
SEGMENT INFORMATION (Notes)
 3 Months Ended
Jan. 31, 2026
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
 
Our President and Chief Executive Officer is the chief operating decision maker ("CODM"). The three operating segments were determined based primarily on how the CODM views and evaluates our operations. The CODM uses segment net revenue and income from operations to assess the performance of the segments by reviewing budget to actual variances on a monthly basis. The CODM also uses segment net revenue and income from operations when making decisions about allocating capital and personnel resources predominantly during the annual strategic planning process. The CODM does not evaluate the segments using asset or liability information.
Description of Segments. We are a global leader in life sciences, diagnostics and applied markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.
A description of our three reportable segments is as follows:
Our Life Sciences and Diagnostics Markets segment is comprised of seven areas of activity. We provide active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables, which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. First, our liquid chromatography and liquid chromatography mass spectrometry businesses enable customers in the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. Second, our electrophoresis and cell phenotyping business delivers end-to-end workflow solutions (including instruments, reagents, consumables, and software) for nucleic acid quality control and multiparametric cell analysis. These offerings support next-
generation sequencing accuracy and enable live-cell imaging, metabolism analysis, and flow cytometry across clinical and life science research applications. Third, our cell imaging and metabolism business provides integrated instruments, reagents, software, and labware for automated imaging, metabolic analysis, plate reading, and dispensing, supporting applications across immunology, oncology, drug discovery, and translational research. Fourth, our specialty contract development and manufacturing organization ("CDMO") business provides services related to and the production of synthesized oligonucleotides under pharmaceutical good manufacturing practices conditions for use as active pharmaceutical ingredients in a class of drugs that utilize nucleic acid molecules for disease therapy. BIOVECTRA capabilities include microbial fermentation, bioreagents, highly potent active pharmaceutical ingredients, peptide purification and biomanufacturing capabilities in several nucleic acid modalities. Together, our BIOVECTRA and nucleic acid solutions businesses comprise our specialty CDMO offerings to our customers providing clinical-to-commercial scale production capabilities. Fifth, our pathology solutions business delivers products for cancer diagnostics and anatomic pathology workflows, including immunohistochemistry, in situ hybridization, hematoxylin and eosin, and special staining. The portfolio also includes clinical flow cytometry reagents and bulk antibodies, as well as assay development services for in vitro diagnostics, biotechnology, and pharmaceutical customers. Sixth, we also collaborate with several major pharmaceutical companies to develop new potential tissue pharmacodiagnostics, also known as companion diagnostics, which may be used to identify patients most likely to benefit from a specific targeted therapy. Finally, our genomics business provides reagents for next-generation sequencing and array workflows, along with solutions that enable clinical labs to identify disease-associated DNA variants and inform cancer therapy.

Our Agilent CrossLab segment provides an extensive services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represents a broad range of offerings designed to serve customer needs across end-markets and applications. Our services portfolio includes repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting and various other custom services to support the customers' laboratory operations. Custom services are tailored to meet the specific application needs of various industries and to keep instruments fully operational and compliant with the respective industry requirements. Our consumables portfolio is designed to improve customer outcomes. Most of the portfolio is vendor neutral, meaning we can serve and supply customers regardless of their instrument purchase choices. Solutions range from chemistries to supplies. Key product categories in consumables include gas chromatography and liquid chromatography columns, sample preparation products, custom chemistries, and a large selection of laboratory supplies. Software and informatics solutions include software for instrument control, data acquisition, data analysis, secure storage of results, and laboratory information and workflow management. This software facilitates the compliant use of instruments in pharmaceutical quality assurance and quality control environments. The OpenLab laboratory software suite is a scalable, open software platform that enables customers to capture, analyze, and share scientific data throughout the lab and across the enterprise. Laboratory automation offers automated sample preparation solutions, including liquid handling, plate management, consumables and scheduling software. These solutions range from standalone automation platforms to integrated workflow solutions with seamless integration to our instrumentation.

Our Applied Markets segment provides application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products. Our gas chromatography and gas chromatography mass spectrometry businesses enable customers to perform a wide variety of testing including measuring volatile and semi-volatile contaminants to assess the safety of our foods, quality of water and consumer products while also enabling testing of fuels and purity of chemicals. Our inductively coupled plasma mass spectrometry, inductively coupled plasma optical emission spectrometry, atomic absorption and microwave plasma-atomic emission spectrometry instruments are vital for our customers to measure metals and elemental signatures in their samples and find uses in the food safety, environmental quality, chemicals manufacture, advanced materials, energy and forensics markets. Our molecular spectroscopy business including the raman, fluorescence and infrared spectroscopy instruments offer both in-field and in-lab testing solutions in a diverse variety of applications including airport security, explosives testing, narcotics, food quality and chemical characterization. Our vacuum business develops cutting edge products and technologies to test vacuum environments and find uses in a diverse variety of industries including semi-conductor, batteries, chemical manufacturing and advanced materials development. Finally, our remarketed instruments business refurbishes and resells certified pre-owned instruments to value-oriented customers who would like Agilent quality and performance at a budget conscious price.
The following tables reflect segment results under our management reporting system after excluding certain unallocated costs as noted in the reconciliations below:
Life Sciences and Diagnostics MarketsAgilent CrossLabApplied MarketsTotal
(in millions)
Three Months Ended January 31, 2026:
Net Revenue$679 $758 $361 $1,798 
Segment Expenses (1)
Cost of products and services336 340 157 
Research and development65 28 24 
Selling, general and administrative169 150 87 
Reportable segment income from operations$109 $240 $93 $442 
Three Months Ended January 31, 2025:
Net Revenue$647 $696 $338 $1,681 
Segment Expenses (1)
Cost of products and services305 306 150 
Research and development63 26 23 
Selling, general and administrative162 143 81 
Reportable segment income from operations$117 $221 $84 $422 
(1) Share-based compensation expense and depreciation expense included in segment expenses are shown below:
Share-Based Compensation ExpenseDepreciation Expense
Three Months Ended January 31,
Three Months Ended January 31,
2026202520262025
(in millions)(in millions)
Life Sciences and Diagnostics Markets$14 $15 $26 $23 
Agilent CrossLab$16 $16 $14 $14 
Applied Markets$7 $8 $6 $6 
The following table reconciles reportable segments' income from operations to Agilent’s total enterprise income before taxes: 
Three Months Ended
 January 31,
 20262025
 (in millions)
Total reportable segment income from operations$442 $422 
Unallocated costs:
Amortization of intangible assets related to business combinations(19)(28)
Acquisition and integration costs(3)(9)
Transformational initiatives(19)(6)
Restructuring and other related costs(20)(1)
Other(28)(2)
Total unallocated costs(89)(46)
Income from operations353 376 
Interest income15 15 
Interest expense(25)(28)
Other income (expense), net21 4 
Income before taxes, as reported$364 $367 
A portion of the segments' expenses arises from shared services and infrastructure that we have historically provided to the segments in order to realize economies of scale and to efficiently use resources. These expenses, collectively called corporate charges, include finance, tax, treasury, legal, real estate, insurance services, workplace services, human resources, information technology services, corporate development and other corporate infrastructure expenses, costs of centralized research and development and joint sales and marketing costs. Charges are allocated to the segments, and the allocations have been determined on a basis that we consider to be a reasonable reflection of the utilization of services provided to or benefits received by the segments. In addition, we do not allocate certain costs to the operating margin for each segment because management does not include this information in its measurement of the performance of the operating segments. Unallocated costs consist of asset impairments, amortization of acquisition-related intangible assets, acquisition and integration costs, transformational initiatives expenses, restructuring and other related costs and certain other charges. Transformational initiatives include expenses associated with targeted cost reduction activities such as manufacturing transfers including costs to move manufacturing, site consolidations, legal entity and other business reorganizations, in-sourcing or outsourcing of activities. Included in this category are also expenses associated with the recent transformation and company programs to transform our product lifecycle management system and human resources and financial systems.
v3.25.4
Insider Trading Arrangements
 3 Months Ended
Jan. 31, 2026
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.25.4
OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 3 Months Ended
Jan. 31, 2026
Accounting Policies [Abstract]  
Overview and Basis of Presentation
Overview. Agilent Technologies, Inc. ("we," "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.

Our fiscal year-end is October 31, and our fiscal quarters end on January 31, April 30 and July 31. Unless otherwise stated, these dates refer to our fiscal year and fiscal quarters.

Basis of Presentation. We have prepared the accompanying financial data for the three months ended January 31, 2026 and 2025 pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles ("GAAP") in the U.S. have been condensed or omitted pursuant to such rules and regulations. The October 31, 2025 condensed balance sheet data was derived from audited financial statements but does not include all the disclosures required in audited financial statements by U.S. GAAP. The accompanying financial data and information should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended October 31, 2025.

In the opinion of management, the accompanying condensed consolidated financial statements contain all normal and recurring adjustments necessary for a fair statement of our condensed consolidated balance sheets as of January 31, 2026 and October 31, 2025, condensed consolidated statement of comprehensive income for the three months ended January 31, 2026 and 2025, condensed consolidated statement of operations for the three months ended January 31, 2026 and 2025, condensed consolidated statement of cash flows for the three months ended January 31, 2026 and 2025 and condensed consolidated statement of equity for the three months ended January 31, 2026 and 2025.

Risks and Uncertainties. We are subject to risks common to companies in the analytical instrument industry, such as global economic and financial market conditions, fluctuations in foreign currency exchange rates and fluctuations in customer demand, among others.

While the tariff changes adversely impacted our costs of revenue during the three months ended January 31, 2026, we expect to fully offset the current impact during our fiscal year 2026. Although the tariff situation is still evolving, we expect to pursue mitigation strategies through supply chain optimization, targeted pricing actions, and other cost-efficiency initiatives to protect margins and sustain long-term growth. Additionally, recent judicial rulings in the U.S. on the legality of certain tariffs imposed and potential future U.S. governmental responses further increase the uncertainty as to the impact of tariffs on our future results of operations. We will continue to monitor these evolving trade dynamics closely, as they may influence future revenue and operational efficiency.
Use of Estimates
Use of Estimates. The preparation of condensed consolidated financial statements in accordance with GAAP in the U.S. requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, valuation of goodwill and purchased intangible assets, inventory valuation, retirement and post-retirement benefit plan assumptions and accounting for income taxes.
Restricted Cash and Restricted Cash Equivalents
Restricted Cash and Restricted Cash Equivalents. Restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets follows:
 January 31,October 31,
 20262025
(in millions)
Cash and cash equivalents$1,758 $1,789 
Restricted cash included in other assets2 2 
Total cash, cash equivalents and restricted cash$1,760 $1,791 
Leases Leases. As of January 31, 2026 and October 31, 2025, operating lease right-of-use assets where we are the lessee were $189 million and $183 million, respectively, and were included within other assets in the accompanying condensed consolidated balance sheets. The associated operating lease liabilities were $196 million and $189 million as of January 31, 2026 and October 31, 2025, respectively, and were included in other accrued liabilities and other long-term liabilities in the accompanying condensed consolidated balance sheets.
Variable Interest Entity
Variable Interest Entities. We make a determination upon entering into an arrangement whether an entity in which we have made an investment is considered a Variable Interest Entity ("VIE"). We evaluate our investments in privately held companies on an ongoing basis. We have determined that as of January 31, 2026 and October 31, 2025, there were no VIEs required to be consolidated in our consolidated financial statements because we do not have a controlling financial interest in any of the VIEs in which we have invested nor are we the primary beneficiary. We account for these investments under either the equity method or as equity investments without readily determinable fair value ("RDFV"), depending on the circumstances. We periodically reassess whether we are the primary beneficiary of a VIE. The reassessment process considers whether we have acquired the power to direct the most significant activities of the VIE through changes in governing documents or other circumstances. We also reconsider whether entities previously determined not to be VIEs have become VIEs and vice-versa, based on changes in facts and circumstances including changes in contractual arrangements and capital structure.

As of January 31, 2026 and October 31, 2025, the total carrying value of investments and loans in privately held companies considered as VIEs was $44 million. The maximum exposure is equal to the carrying value because we do not have future funding commitments. The investments are classified as long-term investments and the loans are classified within other current assets and other assets (depending upon tenure of loan) on the condensed consolidated balance sheets.
Fair Value of Financial Instruments
Fair Value of Financial Instruments. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of long-term equity investments which are readily determinable, and which are not accounted under the equity method are reported at fair value using quoted market prices for those securities when available with gains and losses included in net income. The fair value of long-term equity investments which are not readily determinable, and which are not accounted under the equity method are reported at cost with adjustments for observable changes in prices or impairments included in net income. As of January 31, 2026 and October 31, 2025, the fair value of the commercial paper approximates its carrying value. As of January 31, 2026, the fair value of our senior notes was $3,207 million with a carrying value of $3,332 million. This compares to the fair value of our senior notes of $3,191 million with a carrying value of $3,330 million as of October 31, 2025. The change in the fair value in the three months ended January 31, 2026 is primarily due to increased market interest rates. The fair value was calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs, for example, interest rate yield curves, foreign exchange rates, and forward and spot prices for currencies are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See Note 9, "Fair Value Measurements" for additional information on fair value of financial instruments.
v3.25.4
OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 3 Months Ended
Jan. 31, 2026
Accounting Policies [Abstract]  
Restrictions on Cash and Cash Equivalents
Restricted Cash and Restricted Cash Equivalents. Restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets follows:
 January 31,October 31,
 20262025
(in millions)
Cash and cash equivalents$1,758 $1,789 
Restricted cash included in other assets2 2 
Total cash, cash equivalents and restricted cash$1,760 $1,791 
v3.25.4
REVENUE (Tables)
 3 Months Ended
Jan. 31, 2026
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:
Three Months Ended January 31,
20262025
Life Sciences and Diagnostics MarketsAgilent CrossLabApplied MarketsTotalLife Sciences and Diagnostics MarketsAgilent CrossLabApplied MarketsTotal
(in millions)
Revenue by Region
Americas$307 $273 $98 $678 $312 $261 $96 $669 
Europe203 215 100 518 190 188 85 463 
Asia Pacific169 270 163 602 145 247 157 549 
Total$679 $758 $361 $1,798 $647 $696 $338 $1,681 
The following table presents the company’s total revenue disaggregated by end markets and by revenue type:
Three Months Ended
January 31,
20262025
(in millions)
Revenue by End Markets
Pharmaceutical and Biotechnology$640 $585 
Diagnostics and Clinical263 240 
Academia and Government130 137 
Chemicals and Advanced Materials422 379 
Food166 168 
Environmental and Forensics177 172 
Total$1,798 $1,681 
Revenue by Type
Instrumentation$658 $625 
Non-instrumentation and other1,140 1,056 
Total$1,798 $1,681 
Contract Liabilities and Changes in Balances
The following table provides information about contract liabilities (deferred revenue) and the changes in the balances during the three months ended January 31, 2026:
Contract
Liabilities
(in millions)
Ending balance as of October 31, 2025$803 
Net revenue deferred in the period301 
Revenue recognized that was included in the contract liability balance at the beginning of the period(250)
Change in deferrals from customer cash advances, net of revenue recognized10 
Currency translation and other adjustments13 
Ending balance as of January 31, 2026$877 
v3.25.4
SHARE-BASED COMPENSATION (Tables)
 3 Months Ended
Jan. 31, 2026
Share-Based Payment Arrangement, Noncash Expense [Abstract]  
Allocated share-based compensation expense disclosure
The impact on our results for share-based compensation was as follows:
 
Three Months Ended
January 31,
 20262025
 (in millions)
Cost of products and services$12 $12 
Research and development5 5 
Selling, general and administrative24 24 
Total share-based compensation expense$41 $41 
Assumptions used to estimate fair value for Stock Options and LTPP
The following assumptions were used to estimate the fair value of awards granted.
 
Three Months Ended
January 31,
 20262025
Stock Option Plans:  
Weighted average risk-free interest rate—4.1%
Dividend yield—0.7%
Weighted average volatility—29%
Expected life—5.5 years
LTPP:
Volatility of Agilent shares29%30%
Volatility of selected peer-company shares
17%-59%
16%-62%
Pair-wise correlation with selected peers24%29%
Post-vest holding restriction discount for all executive awards(1)
6.5%6.7%
 _________________________________________________________________________________
(1) For the three months ended January 31, 2026, post-vest holding restriction discount assumption relates to LTPP awards granted to our senior management employees before November 1, 2025.
v3.25.4
NET INCOME PER SHARE (Tables)
 3 Months Ended
Jan. 31, 2026
Earnings Per Share [Abstract]  
Reconciliation of the numerators and denominators of the basic and diluted net income per share
The following is a reconciliation of the numerator and denominator of the basic and diluted net income per share computations for the periods presented below:
 
Three Months Ended
January 31,
 20262025
 (in millions)
Numerator:  
Net income$305 $318 
Denominator:
Basic weighted-average shares283 285 
Potential common shares— stock options and other employee stock plans1 2 
Diluted weighted-average shares284 287 
v3.25.4
INVENTORY (Tables)
 3 Months Ended
Jan. 31, 2026
Inventory, Net [Abstract]  
INVENTORY INVENTORY
 
Inventory as of January 31, 2026 and October 31, 2025 consisted of the following:

 January 31,
2026		October 31,
2025
 (in millions)
Finished goods$546 $547 
Purchased parts and fabricated assemblies513 478 
Inventory$1,059 $1,025 
v3.25.4
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)
 3 Months Ended
Jan. 31, 2026
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill balances and movements for each reportable segment during the period
The following table presents goodwill balances and the movements for each of our reportable segments during the three months ended January 31, 2026:
 
 Life Sciences and
Diagnostics Markets		Agilent CrossLabApplied MarketsTotal
 (in millions)
Goodwill as of October 31, 2025$2,996 $1,168 $309 $4,473 
Foreign currency translation impact1 3 7 11 
Goodwill as of January 31, 2026$2,997 $1,171 $316 $4,484 
Components of other intangible assets during the period
The component parts of other intangible assets as of October 31, 2025 and January 31, 2026 are shown in the table below:
 
 Other Intangible Assets
 Gross
Carrying
Amount		Accumulated
Amortization		Net Book
Value
 (in millions)
As of October 31, 2025   
Purchased technology$1,484 $1,235 $249 
Trademark/Trade name199 181 18 
Customer relationships289 129 160 
Backlog9 2 7 
Third-party technology and licenses34 23 11 
Total amortizable intangible assets$2,015 $1,570 $445 
As of January 31, 2026   
Purchased technology$1,488 $1,249 $239 
Trademark/Trade name198 182 16 
Customer relationships289 135 154 
Backlog9 2 7 
Third-party technology and licenses34 24 10 
Total amortizable intangible assets$2,018 $1,592 $426 
Schedule of estimated future amortization expense of finite-lived intangible assets
Future amortization expense related to existing finite-lived purchased intangible assets for the remainder of fiscal year 2026 and for each of the next five fiscal years and thereafter is estimated below:
Estimated future amortization expense:
(in millions)
Remainder of 2026$56 
2027$72 
2028$65 
2029$61 
2030$52 
2031$47 
Thereafter$73 
v3.25.4
FAIR VALUE MEASUREMENTS (Tables)
 3 Months Ended
Jan. 31, 2026
Fair Value Disclosures [Abstract]  
Fair Value Assets And Liabilities Measured On Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis as of January 31, 2026 were as follows:
 
  Fair Value Measurement at January 31, 2026 Using
 January 31,
2026
Quoted Prices
 in Active
 Markets for
 Identical Assets
 (Level 1)
Significant
 Other
 Observable
 Inputs
 (Level 2)
Significant
 Unobservable
 Inputs
 (Level 3)
 (in millions)
Assets:    
Short-term    
Cash equivalents (money market funds)$1,093 $1,093 $— $— 
Derivative instruments (foreign exchange contracts)11 — 11 — 
Long-term
Trading securities42 42 — — 
Other investments39 — 39 — 
Total assets measured at fair value$1,185 $1,135 $50 $— 
Liabilities:    
Short-term
Derivative instruments (foreign exchange contracts) $14 $— $14 $— 
Long-term
Deferred compensation liability42 — 42 — 
Total liabilities measured at fair value$56 $— $56 $— 

Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2025 were as follows:
 
  Fair Value Measurement at October 31, 2025 Using
 October 31,
2025
Quoted Prices
 in Active
 Markets for
 Identical Assets
 (Level 1)
Significant
 Other
 Observable
 Inputs
 (Level 2)
Significant
 Unobservable
 Inputs
 (Level 3)
 (in millions)
Assets:    
Short-term    
Cash equivalents (money market funds)$1,614 $1,614 $— $— 
Derivative instruments (foreign exchange contracts)14 — 14 — 
Long-term
Trading securities41 41 — — 
Other investments37 — 37 — 
Total assets measured at fair value$1,706 $1,655 $51 $— 
Liabilities:    
Short-term
Derivative instruments (foreign exchange contracts)$10 $— $10 $— 
Long-term
Deferred compensation liability41 — 41 — 
Total liabilities measured at fair value$51 $— $51 $— 
Gain (Loss) on Securities
Gains and losses reflected in other income (expense), net for our equity investments with readily determinable fair value ("RDFV") and equity investments without RDFV are summarized below:
Three Months Ended
January 31,
20262025
(in millions)
Net gain (loss) recognized during the period on equity securities$2 $1 
Less: Net gain (loss) on equity securities sold during the period$— $— 
Unrealized gain (loss) on equity securities $2 $1 
v3.25.4
DERIVATIVES (Tables)
 3 Months Ended
Jan. 31, 2026
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Aggregated notional amounts by designation
The number of open foreign exchange forward contracts and aggregated notional amounts by designation as of January 31, 2026 were as follows:

 Number of Open Forward
Contracts 		Aggregate Notional Amount
USD
Buy/(Sell)
 ($ in millions)
Derivatives designated as hedging instruments:
Cash Flow Hedges
Foreign exchange forward contracts384$(503)
Net Investment Hedges
Foreign exchange forward contracts3$(35)
Derivatives not designated as hedging instruments:
Foreign exchange forward contracts181$(135)
Gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheets in accordance with the authoritative guidance.
The gross fair values and balance sheet location of derivative instruments held in the condensed consolidated balance sheets as of January 31, 2026, and October 31, 2025, were as follows:

Fair Values of Derivative Instruments
Asset DerivativesLiability Derivatives
 Fair Value Fair Value
Balance Sheet LocationJanuary 31,
2026		October 31, 2025Balance Sheet LocationJanuary 31,
2026		October 31,
2025
(in millions)
Derivatives designated as hedging instruments:     
Cash flow hedges 
Foreign exchange contracts
Other current assets$5 $9 Other accrued liabilities$8 $3 
Net investment hedges
Foreign exchange contracts
Other current assets$— $— Other accrued liabilities$1 $— 
Derivatives not designated as hedging instruments:     
Foreign exchange contracts     
Other current assets$6 $5 Other accrued liabilities$5 $7 
Total derivatives$11 $14  $14 $10 
Effect of derivative instruments for foreign exchange contracts in the consolidated statement of operations
The effects of derivative instruments for foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our condensed consolidated statement of operations were as follows:
Three Months Ended
January 31,
20262025
 (in millions)
Derivatives designated as hedging instruments:  
Cash Flow Hedges
Foreign exchange contracts:
Gain (loss) recognized in accumulated other comprehensive income (loss)$(10)$14 
Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales$(1)$3 
Gain (loss) reclassified from accumulated other comprehensive income (loss) into interest expense$(1)$— 
Gain on time value of forward contracts recorded in cost of sales$2 $1 
Net Investment Hedges
Foreign exchange contracts:
Gain (loss) recognized in accumulated other comprehensive income (loss) - translation adjustment$(1)$2 
Derivatives not designated as hedging instruments:
Gain (loss) recognized in other income (expense), net$1 $(2)
v3.25.4
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Tables)
 3 Months Ended
Jan. 31, 2026
Defined Benefit Plan, Net Periodic Benefit Cost (Income)  
Schedule of net pension and post-retirement benefit costs
Components of net periodic benefit cost (income). For the three months ended January 31, 2026 and 2025, our net pension and post retirement benefit cost (income) were comprised of the following:
 
Three Months Ended January 31,
 U.S.
Defined Benefit Plans		Non-U.S.
Defined Benefit Plans		U.S. Post Retirement
Benefit Plans
 202620252026202520262025
 (in millions)
Service cost - benefits earned during the period$— $— $6 $5 $— $— 
Interest cost on benefit obligation5 5 5 6 1 — 
Expected return on plan assets(6)(6)(12)(11)(2)(1)
Amortization of net actuarial (gain) loss— — (7)(6)— — 
Total net periodic benefit cost (income)$(1)$(1)$(8)$(6)$(1)$(1)
Settlements (gain) loss$— $— $— $14 $— $— 
The service cost component is recorded in cost of sales and operating expenses in the condensed consolidated statement of operations. All other cost components are recorded in other income (expense), net in the condensed consolidated statement of operations.
Employer Contributions and Expected Employer Contributions
Employer contributions and expected future employer contributions for the remainder of the year were as follows:
Three Months Ended Employer Contributions
January 31,For Remainder of Year
202620252026
(in millions)
U.S. defined benefit plans$— $— $— 
Non-U.S. defined benefit plans$6 $6 $15 
v3.25.4
WARRANTIES AND CONTINGENCIES (Table)
 3 Months Ended
Jan. 31, 2026
Commitments and Contingencies Disclosure [Abstract]  
Standard warranty
A summary of the standard warranty accrual activity is shown in the table below:
 
 Three Months Ended
January 31,
 20262025
 (in millions)
Standard warranty accrual, beginning balance$28 $30 
Accruals for warranties including change in estimates14 12 
Settlements made during the period(14)(13)
Standard warranty accrual, ending balance$28 $29 
Accruals for warranties due within one year$28 $29 
v3.25.4
RESTRUCTURING AND OTHER RELATED COSTS (Tables)
 3 Months Ended
Jan. 31, 2026
Restructuring and Related Activities [Abstract]  
Schedule of Restructuring Reserve by Type of Cost
A summary of our aggregate liability relating to the fiscal year 2025 restructuring plan and the total restructuring expense since inception of the plan are shown in the table below:

Workforce Reduction
Total
(in millions)
Balance at October 31, 2025$18 
Income statement expense20 
Non-cash settlement (accelerated share-based compensation expense)(3)
Cash payments(19)
Balance at January 31, 2026$16 
Total restructuring expense since inception of FY25 Plan$101 
Restructuring and related costs by statement of operations caption
A summary of the charges in the condensed consolidated statement of operations resulting from restructuring activity is shown below:


Three Months Ended
January 31,
20262025
(in millions)
Cost of products and services$5 $— 
Research and development— — 
Selling, general and administrative(1)
15 1 
Total restructuring expense$20 $1 
___________________________________________________________________________________________________
(1) For the three months ended January 31, 2025, selling, general and administrative expense includes restructuring expense of $1 million related to the fiscal year 2024 restructuring plan that was completed in fiscal year 2025.
v3.25.4
LONG-TERM DEBT (Tables)
 3 Months Ended
Jan. 31, 2026
Debt Disclosure [Abstract]  
Schedule of Senior Notes
The following table summarizes the company’s long-term senior notes:
 
 January 31, 2026October 31, 2025
 Amortized
Principal		Amortized
Principal
(in millions)
2027 Senior Notes597 597 
2029 Senior Notes497 497 
2030 Senior Notes498 498 
2031 Senior Notes846 845 
2034 Senior Notes594 593 
Total Senior Notes$3,032 $3,030 
v3.25.4
STOCKHOLDERS' EQUITY (Tables)
 3 Months Ended
Jan. 31, 2026
Schedule of Accumulated Other Comprehensive Income (Loss)
Changes in accumulated other comprehensive income (loss) by component and related tax effects were as follows:
Net defined benefit pension cost and post retirement plan costs
Three Months Ended January 31, 2026Foreign currency translationPrior service creditsActuarial LossesUnrealized gains (losses) on derivativesTotal
(in millions)
As of October 31, 2025$(297)$120 $(64)$15 $(226)
Other comprehensive income (loss) before reclassifications51 — 4 (10)45 
Amounts reclassified out of accumulated other comprehensive income (loss)— — (7)2 (5)
Tax (expense) benefit— — — 2 2 
Other comprehensive income (loss)51 — (3)(6)42 
As of January 31, 2026$(246)$120 $(67)$9 $(184)
Reclassification out of Accumulated Other Comprehensive Income
Reclassifications out of accumulated other comprehensive income (loss) for the three months ended January 31, 2026 and 2025 were as follows (in millions):
Details about accumulated other
comprehensive income (loss) components		Amounts Reclassified from
other comprehensive income (loss)		Affected line item in
statement of operations
Three Months Ended
January 31,
20262025
Unrealized gain (loss) on derivatives(1)3 Cost of products
Unrealized gain (loss) on derivatives(1)— Interest expense
(2)3 Total before income tax
1 (1)(Provision) benefit for income tax
(1)2 Total net of income tax
Net defined benefit pension cost and post retirement plan costs:
Actuarial net gain (loss)7 — Other income (expense), net
7 — Total before income tax
(1)— (Provision) benefit for income tax
6 — Total net of income tax
Total reclassifications for the period$5 $2 

Amounts in parentheses indicate reductions to income and increases to other comprehensive income (loss).
v3.25.4
SEGMENT INFORMATION (Tables)
 3 Months Ended
Jan. 31, 2026
Segment Reporting [Abstract]  
Segment Profitability and Segment Assets
The following tables reflect segment results under our management reporting system after excluding certain unallocated costs as noted in the reconciliations below:
Life Sciences and Diagnostics MarketsAgilent CrossLabApplied MarketsTotal
(in millions)
Three Months Ended January 31, 2026:
Net Revenue$679 $758 $361 $1,798 
Segment Expenses (1)
Cost of products and services336 340 157 
Research and development65 28 24 
Selling, general and administrative169 150 87 
Reportable segment income from operations$109 $240 $93 $442 
Three Months Ended January 31, 2025:
Net Revenue$647 $696 $338 $1,681 
Segment Expenses (1)
Cost of products and services305 306 150 
Research and development63 26 23 
Selling, general and administrative162 143 81 
Reportable segment income from operations$117 $221 $84 $422 
(1) Share-based compensation expense and depreciation expense included in segment expenses are shown below:
Share-Based Compensation ExpenseDepreciation Expense
Three Months Ended January 31,
Three Months Ended January 31,
2026202520262025
(in millions)(in millions)
Life Sciences and Diagnostics Markets$14 $15 $26 $23 
Agilent CrossLab$16 $16 $14 $14 
Applied Markets$7 $8 $6 $6 
Reconciliation of segment results to total enterprise results
The following table reconciles reportable segments' income from operations to Agilent’s total enterprise income before taxes: 
Three Months Ended
 January 31,
 20262025
 (in millions)
Total reportable segment income from operations$442 $422 
Unallocated costs:
Amortization of intangible assets related to business combinations(19)(28)
Acquisition and integration costs(3)(9)
Transformational initiatives(19)(6)
Restructuring and other related costs(20)(1)
Other(28)(2)
Total unallocated costs(89)(46)
Income from operations353 376 
Interest income15 15 
Interest expense(25)(28)
Other income (expense), net21 4 
Income before taxes, as reported$364 $367 
v3.25.4
OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)
$ in Millions
Jan. 31, 2026
Oct. 31, 2025
Jan. 31, 2025
Oct. 31, 2024
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents        
Cash and cash equivalents $ 1,758 $ 1,789    
Restricted Cash included in other assets 2 2    
Cash, cash equivalents, restricted cash and restricted cash equivalents 1,760 1,791 $ 1,470 $ 1,332
Operating Leases        
Right-of-Use Asset $ 189 $ 183    
Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Other assets Other assets    
Operating lease liability $ 196 $ 189    
Operating Lease Liability, Statement of Financial Position [Extensible Enumeration] Other accrued liabilities, Other long-term liabilities Other accrued liabilities, Other long-term liabilities    
Variable Interest Entity        
Noncontrolling Interest in Variable Interest Entity $ 44 $ 44    
Fair Value of Financial Instruments        
Carrying Value of Senior Notes 3,332 3,330    
Quoted Prices in Active Markets for Identical Assets (Level 1) | Senior Notes        
Fair Value of Financial Instruments        
Fair Value of Senior Notes $ 3,207 $ 3,191    
v3.25.4
REVENUE- Revenue by Region (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Disaggregation of Revenue [Line Items]    
Net revenue $ 1,798 $ 1,681
Life Sciences and Diagnostics Markets    
Disaggregation of Revenue [Line Items]    
Net revenue 679 647
Agilent CrossLab    
Disaggregation of Revenue [Line Items]    
Net revenue 758 696
Applied Markets    
Disaggregation of Revenue [Line Items]    
Net revenue 361 338
Americas    
Disaggregation of Revenue [Line Items]    
Net revenue 678 669
Americas | Life Sciences and Diagnostics Markets    
Disaggregation of Revenue [Line Items]    
Net revenue 307 312
Americas | Agilent CrossLab    
Disaggregation of Revenue [Line Items]    
Net revenue 273 261
Americas | Applied Markets    
Disaggregation of Revenue [Line Items]    
Net revenue 98 96
Europe    
Disaggregation of Revenue [Line Items]    
Net revenue 518 463
Europe | Life Sciences and Diagnostics Markets    
Disaggregation of Revenue [Line Items]    
Net revenue 203 190
Europe | Agilent CrossLab    
Disaggregation of Revenue [Line Items]    
Net revenue 215 188
Europe | Applied Markets    
Disaggregation of Revenue [Line Items]    
Net revenue 100 85
Asia Pacific    
Disaggregation of Revenue [Line Items]    
Net revenue 602 549
Asia Pacific | Life Sciences and Diagnostics Markets    
Disaggregation of Revenue [Line Items]    
Net revenue 169 145
Asia Pacific | Agilent CrossLab    
Disaggregation of Revenue [Line Items]    
Net revenue 270 247
Asia Pacific | Applied Markets    
Disaggregation of Revenue [Line Items]    
Net revenue $ 163 $ 157
v3.25.4
REVENUE - Revenue by End Markets (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Disaggregation of Revenue [Line Items]    
Net revenue $ 1,798 $ 1,681
Pharmaceutical and Biotechnology Market    
Disaggregation of Revenue [Line Items]    
Net revenue 640 585
Diagnostics and Clinical Market    
Disaggregation of Revenue [Line Items]    
Net revenue 263 240
Academia and Government Market    
Disaggregation of Revenue [Line Items]    
Net revenue 130 137
Chemicals and Advanced Materials Market    
Disaggregation of Revenue [Line Items]    
Net revenue 422 379
Food Market    
Disaggregation of Revenue [Line Items]    
Net revenue 166 168
Environmental and Forensics Market    
Disaggregation of Revenue [Line Items]    
Net revenue $ 177 $ 172
v3.25.4
REVENUE - Revenue by Type (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Disaggregation of Revenue [Line Items]    
Net revenue $ 1,798 $ 1,681
Instrumentation    
Disaggregation of Revenue [Line Items]    
Net revenue 658 625
Non-Instrumentation and Other    
Disaggregation of Revenue [Line Items]    
Net revenue $ 1,140 $ 1,056
v3.25.4
REVENUE - Contract Assets and Liability (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Oct. 31, 2025
Contract Asset      
Contract Assets (Unbilled Accounts Receivable) $ 286   $ 329
Contract Liability      
Contract liability ending balance as of October 31, 2025 803    
Net revenue deferred in the period 301    
Revenue recognized that was included in the contract liability balance at the beginning of the period (250) $ (230)  
Change in deferrals from customer cash advances, net of revenue recognized 10    
Currency Translation and Other Adjustment 13    
Contract liability ending balance as of January 31, 2026 $ 877    
v3.25.4
REVENUE - Remaining Performance Obligation (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-31
$ in Millions
Jan. 31, 2026
USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Remaining performance obligation expected timing of satisfaction period 12 months
Remaining performance obligation amount $ 459
v3.25.4
SHARE-BASED COMPENSATION Text (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Oct. 31, 2025
Share-based Compensation Arrangement by Share-based Payment Award      
Share-Based Payment Compensation, Amount Capitalized in Inventory $ 0   $ 0
Employee Stock [ESPP]      
Share-based Compensation Arrangement by Share-based Payment Award      
ESPP plan purchase price (in hundredths) 85.00% 85.00%  
Share-based Payment Arrangement, Option [Member]      
Share-based Compensation Arrangement by Share-based Payment Award      
Vesting percentage 25.00% 25.00%  
Vesting Period 4 years 4 years  
Maximum contractual term, Expiration Period 10 years 10 years  
Exercise Price of Common Stock, Percent of FMV 100.00% 100.00%  
Restricted Stock Units (RSUs)      
Share-based Compensation Arrangement by Share-based Payment Award      
Vesting percentage 25.00% 25.00%  
Vesting Period 4 years 4 years  
Minimum | Performance Shares [LTPP]      
Share-based Compensation Arrangement by Share-based Payment Award      
Vesting percentage 0.00% 0.00%  
Maximum | Performance Shares [LTPP]      
Share-based Compensation Arrangement by Share-based Payment Award      
Vesting percentage 200.00% 200.00%  
v3.25.4
SHARE-BASED COMPENSATION Allocated Share-based compensation expense (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Employee Service Share-based Compensation, Allocation of Recognized Period Costs    
Share-based compensation expense $ 41 $ 41
Cost of Products and Services    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs    
Share-based compensation expense 12 12
Research and Development    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs    
Share-based compensation expense 5 5
Selling, General and Administrative    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs    
Share-based compensation expense $ 24 $ 24
v3.25.4
SHARE-BASED COMPENSATION Fair Value Assumptions (Details)
 3 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Share-based Payment Arrangement, Option [Member]    
Share-based Compensation Arrangement by Share-based Payment Award    
Weighted average risk-free interest rate   4.10%
Dividend yield   0.70%
Weighted average volatility   29.00%
Expected Life   5 years 6 months
LTPP & RSU    
Share-based Compensation Arrangement by Share-based Payment Award    
Post-vest holding restriction discount for all executive awards   6.70%
Performance Shares [LTPP]    
Share-based Compensation Arrangement by Share-based Payment Award    
Volatility of Agilent shares 29.00% 30.00%
Volatility of selected peer-company shares - Minimum 17.00% 16.00%
Volatility of selected peer-company shares - Maximum 59.00% 62.00%
Pair-wise correlation with selected peers (in hundredths) 24.00% 29.00%
Post-vest holding restriction discount for all executive awards 6.50%  
v3.25.4
INCOME TAXES (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Income Tax Disclosure    
Provision (benefit) for income taxes $ 59 $ 49
Effective income tax rate 16.20% 13.40%
v3.25.4
NET INCOME PER SHARE (Details) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Numerator:    
Net income $ 305 $ 318
Denominators:    
Basic weighted-average shares 283 285
Potential common shares - stock options and other employee stock plans 1 2
Diluted weighted average shares 284 287
Anti-dilutive shares excluded from computation of dilutive earnings per share (in shares) 0 0
v3.25.4
INVENTORY (Details) - USD ($)
$ in Millions
Jan. 31, 2026
Oct. 31, 2025
Inventory, Net [Abstract]    
Finished goods $ 546 $ 547
Purchased parts and fabricated assemblies 513 478
Inventory $ 1,059 $ 1,025
v3.25.4
GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill Roll forward (Details)
$ in Millions
 3 Months Ended
Jan. 31, 2026
USD ($)
Goodwill Roll Forward  
Goodwill beginning balance $ 4,473
Foreign currency translation impact 11
Goodwill ending balance 4,484
Goodwill arising from acquisitions 0
Life Sciences and Diagnostics Markets  
Goodwill Roll Forward  
Goodwill beginning balance 2,996
Foreign currency translation impact 1
Goodwill ending balance 2,997
Agilent CrossLab  
Goodwill Roll Forward  
Goodwill beginning balance 1,168
Foreign currency translation impact 3
Goodwill ending balance 1,171
Applied Markets  
Goodwill Roll Forward  
Goodwill beginning balance 309
Foreign currency translation impact 7
Goodwill ending balance $ 316
v3.25.4
GOODWILL AND OTHER INTANGIBLE ASSETS Disclosures and Components of Purchased Other Intangibles (Details) - USD ($)
$ in Millions
Jan. 31, 2026
Oct. 31, 2025
Finite-Lived Intangible Assets, Net    
Total Intangible Assets $ 2,018 $ 2,015
Accumulated Amortization 1,592 1,570
Net Book Value 426 445
Purchased Technology    
Finite-Lived Intangible Assets, Net    
Gross Carrying Amount 1,488 1,484
Accumulated Amortization 1,249 1,235
Net Book Value 239 249
Trademark/Tradenames    
Finite-Lived Intangible Assets, Net    
Gross Carrying Amount 198 199
Accumulated Amortization 182 181
Net Book Value 16 18
Customer Relationships    
Finite-Lived Intangible Assets, Net    
Gross Carrying Amount 289 289
Accumulated Amortization 135 129
Net Book Value 154 160
Backlog    
Finite-Lived Intangible Assets, Net    
Gross Carrying Amount 9 9
Accumulated Amortization 2 2
Net Book Value 7 7
Third-Party Technology and Licenses    
Finite-Lived Intangible Assets, Net    
Gross Carrying Amount 34 34
Accumulated Amortization 24 23
Net Book Value $ 10 $ 11
v3.25.4
GOODWILL AND OTHER INTANGIBLE ASSETS Textuals (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Finite-Lived Intangible Assets    
Additions to goodwill $ 0  
Addition to other intangible assets 0  
Foreign currency translation impact on other intangible assets increase (decrease) 0  
Goodwill impairment 0 $ 0
Impairment of IPR&D 0 0
Amortization of intangible assets during the period $ 19 $ 28
v3.25.4
GOODWILL AND OTHER INTANGIBLE ASSETS - Estimated Future Amortization (Details)
$ in Millions
Jan. 31, 2026
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
Remainder of 2026 $ 56
2027 72
2028 65
2029 61
2030 52
2031 47
Thereafter $ 73
v3.25.4
FAIR VALUE MEASUREMENTS, Fair value of assets and liabilities measured on a recurring basis (Details) - Fair Value, Measurements, Recurring - USD ($)
$ in Millions
Jan. 31, 2026
Oct. 31, 2025
Assets    
Total assets measured at fair value $ 1,185 $ 1,706
Liabilities    
Total liabilities measured at fair value 56 51
Other Current Assets    
Assets    
Cash equivalents (money market funds) 1,093 1,614
Derivative instruments (foreign exchange contracts) 11 14
Other assets    
Assets    
Trading securities 42 41
Other investments 39 37
Other accrued liabilities    
Liabilities    
Derivative instruments (foreign exchange contracts) 14 10
Other long-term liabilities    
Liabilities    
Deferred compensation liability 42 41
Quoted Prices in Active Markets for Identical Assets (Level 1)    
Assets    
Total assets measured at fair value 1,135 1,655
Liabilities    
Total liabilities measured at fair value 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Other Current Assets    
Assets    
Cash equivalents (money market funds) 1,093 1,614
Derivative instruments (foreign exchange contracts) 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Other assets    
Assets    
Trading securities 42 41
Other investments 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Other accrued liabilities    
Liabilities    
Derivative instruments (foreign exchange contracts) 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Other long-term liabilities    
Liabilities    
Deferred compensation liability 0 0
Significant Other Observable Inputs (Level 2)    
Assets    
Total assets measured at fair value 50 51
Liabilities    
Total liabilities measured at fair value 56 51
Significant Other Observable Inputs (Level 2) | Other Current Assets    
Assets    
Cash equivalents (money market funds) 0 0
Derivative instruments (foreign exchange contracts) 11 14
Significant Other Observable Inputs (Level 2) | Other assets    
Assets    
Trading securities 0 0
Other investments 39 37
Significant Other Observable Inputs (Level 2) | Other accrued liabilities    
Liabilities    
Derivative instruments (foreign exchange contracts) 14 10
Significant Other Observable Inputs (Level 2) | Other long-term liabilities    
Liabilities    
Deferred compensation liability 42 41
Significant Unobservable Inputs (Level 3)    
Assets    
Total assets measured at fair value 0 0
Liabilities    
Total liabilities measured at fair value 0 0
Significant Unobservable Inputs (Level 3) | Other Current Assets    
Assets    
Cash equivalents (money market funds) 0 0
Derivative instruments (foreign exchange contracts) 0 0
Significant Unobservable Inputs (Level 3) | Other assets    
Assets    
Trading securities 0 0
Other investments 0 0
Significant Unobservable Inputs (Level 3) | Other accrued liabilities    
Liabilities    
Derivative instruments (foreign exchange contracts) 0 0
Significant Unobservable Inputs (Level 3) | Other long-term liabilities    
Liabilities    
Deferred compensation liability $ 0 $ 0
v3.25.4
FAIR VALUE MEASUREMENTS - Equity Securities and Investments (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Fair Value Disclosures [Abstract]    
Net gain (loss) on equity securities $ 2 $ 1
Equity Securities, FV-NI, Realized Gain (Loss) 0 0
Unrealized gain (loss) on equity securities 2 1
Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount $ 0 $ 0
v3.25.4
FAIR VALUE MEASUREMENTS, Assets and Liabilities measured at Fair Value on a Non-Recurring Basis (Details) - Fair Value, Nonrecurring - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Long-Lived Assets    
Impairment of Long-Lived Assets Held-for-use $ 0 $ 0
Impairment of Long-Lived assets Held for sale $ 0 $ 0
v3.25.4
FAIR VALUE MEASUREMENTS, Non Marketable Securities (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Fair Value Disclosures [Abstract]    
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount $ 0 $ 0
Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount 0 1
Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 0 0
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount 42 40
Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount 71 31
Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount 26 0
Non-marketable equity securities carrying amount $ 55 $ 100
v3.25.4
DERIVATIVES- Text (Details)
$ in Millions
 3 Months Ended
Sep. 06, 2019
USD ($)
Sep. 15, 2016
USD ($)
Jan. 31, 2026
USD ($)
Aug. 16, 2019
USD ($)
Feb. 01, 2016
USD ($)
contracts
Derivative Instruments and Hedging Activities Disclosure          
Aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position     $ 9    
Senior Notes 2026 | Interest Rate Swap | Derivatives Designated as Hedging Instrument | Cash Flow Hedging          
Terminated Derivative Contracts          
Number of interest rate swap contracts terminated | contracts         3
Derivative, Notional Amount         $ 300
Remaining Gain (Loss) Reclassification from Accumulated OCI to be amortized to Income,   $ (10) (1)    
Senior Notes 2029 | Treasury Lock [Member] | Derivatives Designated as Hedging Instrument | Cash Flow Hedging          
Terminated Derivative Contracts          
Derivative, Notional Amount       $ 250  
Remaining Gain (Loss) Reclassification from Accumulated OCI to be amortized to Income, $ (6)   $ (2)    
v3.25.4
DERIVATIVES- Foreign Exchange Forward Contracts (Details)
$ in Millions
Jan. 31, 2026
USD ($)
contracts
Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Foreign Exchange Forward  
Derivative  
Number of foreign exchange forward contracts (in units) | contracts 384
Derivatives Designated as Hedging Instrument | Net Investment Hedging | Foreign Exchange Forward  
Derivative  
Number of foreign exchange forward contracts (in units) | contracts 3
Derivatives Not Designated as Hedging Instruments | Foreign Exchange Forward  
Derivative  
Number of foreign exchange forward contracts (in units) | contracts 181
Sell | Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Forward Contracts USD  
Derivative  
Derivative, Notional Amount | $ $ 503
Sell | Derivatives Designated as Hedging Instrument | Net Investment Hedging | Forward Contracts USD  
Derivative  
Derivative, Notional Amount | $ 35
Sell | Derivatives Not Designated as Hedging Instruments | Forward Contracts USD  
Derivative  
Derivative, Notional Amount | $ $ 135
v3.25.4
DERIVATIVES, Fair value of derivative instruments and Consolidated Balance Sheet location (Details) - USD ($)
$ in Millions
Jan. 31, 2026
Oct. 31, 2025
Derivative Fair Value by Balance Sheet Location    
Derivatives asset fair value $ 11 $ 14
Derivatives liabilities fair value 14 10
Derivatives Designated as Hedging Instruments | Cash Flow Hedging | Foreign Exchange Contracts | Other Current Assets    
Derivative Fair Value by Balance Sheet Location    
Derivatives asset fair value 5 9
Derivatives Designated as Hedging Instruments | Cash Flow Hedging | Foreign Exchange Contracts | Other Accrued Liabilities    
Derivative Fair Value by Balance Sheet Location    
Derivatives liabilities fair value 8 3
Derivatives Designated as Hedging Instruments | Net Investment Hedging | Foreign Exchange Contracts | Other Current Assets    
Derivative Fair Value by Balance Sheet Location    
Derivatives asset fair value 0 0
Derivatives Designated as Hedging Instruments | Net Investment Hedging | Foreign Exchange Contracts | Other Accrued Liabilities    
Derivative Fair Value by Balance Sheet Location    
Derivatives liabilities fair value 1 0
Derivatives Not Designated as Hedging Instruments | Foreign Exchange Contracts | Other Current Assets    
Derivative Fair Value by Balance Sheet Location    
Derivatives asset fair value 6 5
Derivatives Not Designated as Hedging Instruments | Foreign Exchange Contracts | Other Accrued Liabilities    
Derivative Fair Value by Balance Sheet Location    
Derivatives liabilities fair value $ 5 $ 7
v3.25.4
DERIVATIVES, Effect of derivative instruments on Consolidated Statement of Operations (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Derivative    
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax $ (2) $ 3
Cost of Products and Services    
Derivative    
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax (1) 3
Interest Expense    
Derivative    
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax (1) 0
Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Foreign Exchange Contracts    
Derivative    
Gain (loss) recognized $ 2 $ 1
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Cost of revenue Cost of revenue
Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Foreign Exchange Contracts | Accumulated Other Comprehensive Income (Loss)    
Derivative    
Gain (loss) recognized in accumulated other comprehensive loss $ (10) $ 14
Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Foreign Exchange Contracts | Cost of Products and Services    
Derivative    
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax (1) 3
Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Foreign Exchange Contracts | Interest Expense    
Derivative    
Gain (loss) reclassified from accumulated other comprehensive loss into Interest expense (1) 0
Derivatives Designated as Hedging Instrument | Net Investment Hedging | Foreign Exchange Contracts | Accumulated Other Comprehensive Income (Loss)    
Derivative    
Gain (loss) recognized in accumulated other comprehensive loss - translation adjustment (1) 2
Derivatives Not Designated as Hedging Instruments    
Derivative    
Gain (loss) recognized $ 1 $ (2)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Other income (expense), net Other income (expense), net
v3.25.4
Derivative Instruments and Hedging Activities (Details) - Cash Flow Hedging
$ in Millions
 3 Months Ended
Jan. 31, 2026
USD ($)
Derivative  
Net gain (loss) to be reclassified within next Twelve Months $ 8
Cost of Products and Services  
Derivative  
Net gain (loss) to be reclassified within next Twelve Months $ (6)
v3.25.4
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS- Components of net periodic costs (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Pension Plan | United States    
Defined Benefit Plan, Net Periodic Benefit Cost (Income)    
Service cost - benefits earned during the period $ 0 $ 0
Interest cost on benefit obligation 5 5
Expected return (loss) on plan assets (6) (6)
Amortization of net actuarial gain (loss) 0 0
Total net periodic benefit cost (income) (1) (1)
Pension Plan | Foreign Plan    
Defined Benefit Plan, Net Periodic Benefit Cost (Income)    
Service cost - benefits earned during the period 6 5
Interest cost on benefit obligation 5 6
Expected return (loss) on plan assets (12) (11)
Amortization of net actuarial gain (loss) 7 6
Total net periodic benefit cost (income) (8) (6)
Curtailments and Settlements    
Settlement (gain) loss   14
Other Postretirement Benefits Plan | United States    
Defined Benefit Plan, Net Periodic Benefit Cost (Income)    
Service cost - benefits earned during the period 0 0
Interest cost on benefit obligation 1 0
Expected return (loss) on plan assets (2) (1)
Amortization of net actuarial gain (loss) 0 0
Total net periodic benefit cost (income) $ (1) $ (1)
v3.25.4
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Details) (Employer Contributions)) - Pension Plan - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Foreign Plan    
Defined Benefit Plan Disclosure    
Employer Contributions $ 6 $ 6
Expected future employer contributions 15  
United States    
Defined Benefit Plan Disclosure    
Employer Contributions 0 $ 0
Expected future employer contributions $ 0  
v3.25.4
WARRANTIES AND CONTINGENCIES (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Oct. 31, 2025
Movement in Standard Product Warranty Accrual      
Beginning balance $ 28 $ 30  
Accruals for warranties including change in estimate 14 12  
Settlements made during the period (14) (13)  
Ending balance at end of period 28 29  
Standard Product Warranty Disclosure      
Accruals for warranties due within one year 28 $ 29  
Guarantees      
Bank Guarantees $ 39   $ 39
v3.25.4
RESTRUCTURING AND OTHER RELATED COSTS - ROLLFORWARD (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Restructuring Cost and Reserve [Line Items]    
Income statement expense $ 20 $ 1
FY25 Restructuring Plan    
Restructuring Cost and Reserve [Line Items]    
Restructuring expense since inception 101  
Employee Severance | FY25 Restructuring Plan    
Restructuring Cost and Reserve [Line Items]    
Restructuring Reserve, Beginning Balance 18  
Income statement expense 20  
Restructuring Reserve, Settled without Cash (3)  
Payments for Restructuring (19)  
Restructuring Reserve, Ending Balance $ 16  
Employee Severance | FY24 Restructuring Plan    
Restructuring Cost and Reserve [Line Items]    
Income statement expense   $ 1
v3.25.4
RESTRUCTURING AND OTHER RELATED COSTS - Income Statement (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Restructuring Cost and Reserve [Line Items]    
Income statement expense $ 20 $ 1
Cost of Products and Services    
Restructuring Cost and Reserve [Line Items]    
Income statement expense 5 0
Research and Development    
Restructuring Cost and Reserve [Line Items]    
Income statement expense 0 0
Selling, General and Administrative    
Restructuring Cost and Reserve [Line Items]    
Income statement expense 15 1
Employee Severance | FY25 Restructuring Plan    
Restructuring Cost and Reserve [Line Items]    
Income statement expense $ 20  
Employee Severance | FY24 Restructuring Plan    
Restructuring Cost and Reserve [Line Items]    
Income statement expense   $ 1
v3.25.4
SHORT-TERM DEBT - Credit Facility (Details) - Line of Credit - USD ($)
$ in Millions
 3 Months Ended
Jun. 07, 2023
Jun. 02, 2023
Jan. 31, 2026
Oct. 31, 2025
Jul. 03, 2023
5 yr Unsecured Credit Facility          
Short-term Debt          
Maximum borrowing capacity of credit facility $ 1,500        
Credit faciity terms (in years) five        
Expiration date of credit facility Jun. 07, 2028        
Proceeds from credit facility     $ 0    
Repayments of credit facility     0    
Amount outstanding on credit facility     0 $ 0  
Incremental Revolving Credit Facility          
Short-term Debt          
Initiation date of credit facility Jun. 07, 2023        
Maximum borrowing capacity of credit facility $ 750        
Expiration date of credit facility Jun. 07, 2028        
Proceeds from credit facility     0    
Repayments of credit facility     0    
Amount outstanding on credit facility     0 0  
Uncommitted Money Market Line Credit Agreement          
Short-term Debt          
Initiation date of credit facility   Jun. 02, 2023      
Maximum borrowing capacity of credit facility   $ 300      
Minimum amount per advance request   $ 1      
Proceeds from credit facility     0    
Repayments of credit facility     0    
Amount outstanding on credit facility     0 0  
Commercial Paper          
Short-term Debt          
Maximum borrowing capacity of credit facility         $ 1,500
Proceeds from issuance of commercial paper     225    
Repayment of commercial paper     225    
Amount outstanding on credit facility     $ 0 $ 0  
v3.25.4
SHORT-TERM DEBT - Senior Notes (Details) - Senior Notes 2026
$ in Millions
Jan. 31, 2026
USD ($)
Short-term Debt  
Stated Interest Rate 3.05%
Senior Notes  
Short-term Debt  
Senior Notes - Current Maturities $ 300
v3.25.4
SHORT-TERM DEBT - Other Loans (Details) - USD ($)
$ in Millions
Jan. 31, 2026
Oct. 31, 2025
Short-term Debt    
Short-term debt $ 304 $ 304
Strategic Innovation Fund    
Short-term Debt    
Debt, Weighted Average Interest Rate 4.70%  
Atlantic Canada Opportunities Agency (ACOA)    
Short-term Debt    
Debt, Weighted Average Interest Rate 4.50%  
Other Loans    
Short-term Debt    
Short-term debt $ 4 $ 4
v3.25.4
LONG-TERM DEBT (Details) - USD ($)
$ in Millions
Jan. 31, 2026
Oct. 31, 2025
Debt Instrument    
Long-term debt $ 3,050 $ 3,050
Senior Notes 2027    
Debt Instrument    
Long-term debt 597 597
Senior Notes 2029    
Debt Instrument    
Long-term debt 497 497
Senior Notes 2030    
Debt Instrument    
Long-term debt 498 498
Senior Notes 2031    
Debt Instrument    
Long-term debt 846 845
Senior Notes 2034    
Debt Instrument    
Long-term debt 594 593
Senior Notes    
Debt Instrument    
Long-term debt $ 3,032 $ 3,030
v3.25.4
LONG-TERM DEBT - Other loans (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Oct. 31, 2025
Debt Instrument      
Long-term debt $ 3,050   $ 3,050
Repayments of Long-Term Debt (2) $ (1)  
Other Loans      
Debt Instrument      
Long-term debt $ 18   $ 20
Strategic Innovation Fund      
Debt Instrument      
Debt, Weighted Average Interest Rate 4.70%    
Atlantic Canada Opportunities Agency (ACOA)      
Debt Instrument      
Debt, Weighted Average Interest Rate 4.50%    
v3.25.4
STOCKHOLDERS' EQUITY - Stock Repurchase Program (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2026
Jan. 31, 2025
May 29, 2024
Jan. 09, 2023
2023 Repurchase Program        
Share Repurchase Program [Line Items]        
Share repurchase program authorized amount       $ 2,000.0
Shares repurchased and retired during period, (Shares)   649,857    
Shares repurchased and retired during period, (Value)   $ 90.0    
2024 Repurchase Program        
Share Repurchase Program [Line Items]        
Share repurchase program authorized amount     $ 2,000.0  
Shares repurchased and retired during period, (Shares) 1,050,000.000      
Shares repurchased and retired during period, (Value) $ 152.0      
Excise Tax on Share Repurchases 0.5      
Remaining authorized repurchase amount under share repurchase program $ 1,797.0      
v3.25.4
STOCKHOLDER"S EQUITY - Dividends (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended
Feb. 11, 2026
Jan. 31, 2026
Jan. 31, 2025
Dividends Paid      
Cash dividends paid per common share   $ 0.255 $ 0.248
Aggregate amount of cash dividends paid   $ 72 $ 71
Dividends Declared      
Dividends Declared. per share   $ 0.255 $ 0.248
Subsequent Event [Member]      
Dividends Declared      
Dividends Declared. per share $ 0.255    
Aggregate Cash Dividends Declared $ 72    
v3.25.4
STOCKHOLDER'S EQUITY - Accumulated Other Comprehensive Income (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Oct. 31, 2025
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $ (184)   $ (226)
Other comprehensive income (loss) before reclassifications 45    
Amounts reclassified out of accumulated other comprehensive income (loss) (5)    
Tax expense (benefit) 2    
Other comprehensive income (loss) 42 $ (76)  
Foreign Currency Translation      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest (246)   (297)
Other comprehensive income (loss) before reclassifications 51    
Amounts reclassified out of accumulated other comprehensive income (loss) 0    
Tax expense (benefit) 0    
Other comprehensive income (loss) 51    
Prior Service Credits      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 120   120
Other comprehensive income (loss) before reclassifications 0    
Amounts reclassified out of accumulated other comprehensive income (loss) 0    
Tax expense (benefit) 0    
Other comprehensive income (loss) 0    
Actuarial Losses      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest (67)   (64)
Other comprehensive income (loss) before reclassifications 4    
Amounts reclassified out of accumulated other comprehensive income (loss) (7)    
Tax expense (benefit) 0    
Other comprehensive income (loss) (3)    
Unrealized Gains (Losses) on Derivatives      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 9   $ 15
Other comprehensive income (loss) before reclassifications (10)    
Amounts reclassified out of accumulated other comprehensive income (loss) 2    
Tax expense (benefit) 2    
Other comprehensive income (loss) $ (6)    
v3.25.4
STOCKHOLDERS' EQUITY - Reclassifications out of accumulated comprehensive income (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]    
Amounts reclassified out of accumulated other comprehensive income (loss) $ (5)  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax (2) $ 3
Amounts reclassified into earnings related to derivative instruments, tax 1 (1)
Unrealized gain (loss) on derivatives after reclassification and after Tax (1) 2
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax (7) 0
Actuarial net loss and prior service benefit reclassified, before tax 7 0
Tax on actuarial net loss and prior service benefit reclassified (1) 0
Actuarial net loss and prior service benefit reclassified, net of tax 6 0
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax 5 2
Cost of Products and Services    
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]    
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax (1) 3
Interest Expense    
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]    
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax $ (1) $ 0
v3.25.4
SEGMENT INFORMATION - Profitability (Details)
$ in Millions
 3 Months Ended
Jan. 31, 2026
USD ($)
Reportable_segment
Jan. 31, 2025
USD ($)
Reportable_segment
Segment Reporting Information    
Number of Reportable Segments | Reportable_segment 3 3
Segment Reporting Information    
Net revenue $ 1,798 $ 1,681
Cost of revenue 852 782
Research and Development Expense 117 113
Selling, General and Administrative Expense 476 410
Income from operations 353 376
Share-based compensation expense 41 41
Operating Segments    
Segment Reporting Information    
Income from operations 442 422
Life Sciences and Diagnostics Markets    
Segment Reporting Information    
Net revenue 679 647
Cost of revenue 336 305
Research and Development Expense 65 63
Selling, General and Administrative Expense 169 162
Life Sciences and Diagnostics Markets | Operating Segments    
Segment Reporting Information    
Income from operations 109 117
Share-based compensation expense 14 15
Depreciation 26 23
Agilent CrossLab    
Segment Reporting Information    
Net revenue 758 696
Cost of revenue 340 306
Research and Development Expense 28 26
Selling, General and Administrative Expense 150 143
Agilent CrossLab | Operating Segments    
Segment Reporting Information    
Income from operations 240 221
Share-based compensation expense 16 16
Depreciation 14 14
Applied Markets    
Segment Reporting Information    
Net revenue 361 338
Cost of revenue 157 150
Research and Development Expense 24 23
Selling, General and Administrative Expense 87 81
Applied Markets | Operating Segments    
Segment Reporting Information    
Income from operations 93 84
Share-based compensation expense 7 8
Depreciation $ 6 $ 6
v3.25.4
SEGMENT INFORMATION - Reconciliation of Reportable Results (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Reconciliation of Operating Profit from Segments to Consolidated    
Income from operations $ 353 $ 376
Restructuring Charges 20 1
Interest income 15 15
Interest expense (25) (28)
Other income (expense), net 21 4
Income before taxes, as reported 364 367
Operating Segments    
Reconciliation of Operating Profit from Segments to Consolidated    
Income from operations 442 422
Segment Reconciling Items    
Reconciliation of Operating Profit from Segments to Consolidated    
Amortization of intangible assets related to business combinations 19 28
Acquisition and integration costs 3 9
Transformational initiatives 19 6
Restructuring Charges 20 1
Other 28 2
Unallocated costs $ 89 $ 46